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ABSTRACT 
With the increasing prevalence of antimicrobial resistance, the escalation of 
opportunistic/pathogenic infections is a looming global crisis. To avoid the pitfalls of 
conventional antibiotics, this dissertation focuses on developing macromolecular 
solutions to develop novel antimicrobial materials based on essential oils (thymol, 
carvacrol, and aldehydes). It is well established that essential oil derivatives exhibit high 
potency towards a wide range of pathogenic microbes. The rapid photopolymerization 
kinetics, limited by-products, and homogeneous network formation afforded by thiol-ene 
photopolymerization are utilized to either encapsulate essential oil derivatives or convert 
them into monomers which can subsequently be incorporated into new antimicrobial 
materials with new structure-function relationships. 
The first chapter of this dissertation outlines the need for alternatives to traditional 
antibiotics and the motivation for developing essential oil-based therapies. In the second 
chapter, the utilization of thiol-ene chemistry in the design of drug delivery and 
encapsulation are reviewed. The third chapter of this dissertation focus on the 
development of one-pot/solvent-free thiol-ene miniemulsion technique to synthesize 
thymol/carvacrol-loaded nanoparticles with high loading capacity (≈50% w/w), excellent 
encapsulation efficiencies (>95%), and potent antimicrobial activity. In the following 
chapters, new pro-antimicrobial networks via degradable acetals (PANDAs) were 
fabricated as a new paradigm for the sequestration and triggered release of volatile, 
antimicrobial aldehydes. PANDAs are crosslinked networks in which every crosslink 
junction contains a degradable acetal linkage. When PANDAs are exposed to neutral to 
acidic conditions (pH < 8), the PANDAs undergo surface erosion and exhibit sustained 
 iii 
aldehyde release from days to months. Chapter IV details the fabrication of PANDAs 
with a synthetic aldehyde, chlorobenzaldehyde, while chapter V emphases on the use of 
the plant-derived, p-anisaldehyde (an extract from star anise). In both chapters, the 
synthesis of PANDAs, thermal/mechanical properties, aldehyde release kinetics, as well 
as antimicrobial efficacy and cytotoxicity were elucidated.
 iv 
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CHAPTER I – ESSENTIAL OILS AS ANTIMICROBIAL AGENTS: CHALLENGES 
AND DESIGN STRATEGIES 
1.1 Antimicrobial Resistance 
With 700,000 annual deaths globally, antimicrobial resistance (AMR) – attributed 
in part to overuse and misuse of antibiotics in medicine and agriculture – is a global crisis 
that seriously threatens the sustainability of public health.1  Without significant steps 
toward solving AMR, a recent review predicts 10 million deaths annually attributed to 
AMR in 2050.1 AMR occurs when pathogenic microbes are able to survive and grow 
after exposure to antibiotics that would normally kill/inhibit their growth.2 Infections 
caused by AMR strains are deadly, difficult to treat with common antibiotics, often 
require toxic/costly treatments, and create broader infection control problems (spreading 
infections globally).3 Compounding the issue of AMR, over 23.5 million Americans are 
more susceptible to common infections due to weakened immune systems (i.e. elderly or 
patients with rheumatoid arthritis, HIV, organ transplants, etc.).4 To mitigate the rapid 
rise of AMR and protect immunocompromised individuals, new antibiotics and new 
approaches to control the spread and evolution of AMR pathogens are required. 
Additionally, a conscious effort to reduce use of antibiotics in medicine and agriculture is 
critical. The continuous emergence of resistant pathogens, scarcity of new antimicrobial 
drug scaffolds in the pharmaceutical discovery pipeline, and public demand for 
antibiotic-free food production have led to growing interest in natural, plant-derived 
extracts, or essential oils, as alternatives and/or supplements to synthetic antibiotics. 
1.2 Essential oils as antimicrobials 
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Essential oils (EOs) are complex mixtures of bioactive phytochemicals, including 
aldehydes, terpenes, terpenoids, and phenolics, that are known to exhibit broad spectrum 
antimicrobial activity and represent an attractive alternative to conventional antibiotics.5-6 
Most EO constituents are selective towards pathogenic bacteria without promoting 
resistance and the Food and Drug Administration has classified many EOs and individual 
constituents of EOs with Generally Regarded as Safe (GRAS) status.3, 7-8 EOs have 
recently found applications as food preservatives9, packaging additives7, textile 
fragrances10, pesticides11, and therapeutic applications12-13. Additionally, EOs have been 
successfully used as an exceptionally potent treatment against biofilm forming bacteria 
Pseudomonas aeruginosa and Staphylococcus aureus.14 EOs as an antimicrobial 
treatment exhibit fewer adverse effects, have higher patient tolerance, and are relatively 
inexpensive compared to traditional antibiotics.3  
Studies have shown that EOs eradicate microbial populations by targeting inner-
and-outer membranes, membrane proteins, and intracellular targets.15 It is important to 
note that determining the mode of action for each EO constituent is not trivial. EO 
constituents have shown to affect multiple-connected pathways without specified 
targets.15 To complicate matters further, different species of bacteria may exhibit 
different responses to each EO constituent. For a review of EO mechanisms of action and 
potential targets, we encourage reading comprehensive reviews by Hyldgaard7, Burt15, 
and Nazzaro16.  
1.3 Essential oil challenges 
Despite historical interest in EOs, significant challenges for practical 
implementation of phytochemicals as antimicrobial agents stem from the hydrophobicity 
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(poor water solubility), volatility, and instability of many EO constituents.17  Poor water 
solubility particularly limits the bioavailability of these compounds and significantly 
lowers biological and antimicrobial activity, whereas volatility is problematic for 
achieving sustained release and controlled delivery. Many strategies have been reported 
to sequester or encapsulate EOs within films or colloidal systems; however, these 
strategies often suffer deficiencies such as low loading, poor encapsulation efficiencies, 
necessity of organic processing solvents, and uncontrolled burst release profiles.18 19 
Encapsulation and controlled/sustained release of EO constituents could help to 
overcome these issues and lead to the wider use of these plant-derived antimicrobials in 
the food industry and agriculture. 
1.4 Encapsulation and release of phytochemicals via the “polyactive” approach. 
Many approaches have been reported to encapsulate hydrophobic EO constituents 
within polymer systems in attempt to address the challenges (poor solubility, volatility, 
oxidative instability, low bioavailability, uncontrolled delivery) associated with 
implementation of EOs as alternative antimicrobials.20-21 Previous studies have shown 
that encapsulating EOs improves both their aqueous stability and increases their 
antimicrobial activity.22 23 These approaches however, predominately focused on physical 
mixtures and non-covalent interactions resulting in low loading, poor encapsulation 
efficiency, and burst release profiles.  Recent work in the area of polyactives offers a 
viable solution to these challenges. “Polyactives” refer to polymeric pro-drugs that 
undergo partial or complete degradation to release active therapeutic agents (e.g., anti-
inflammatory, antioxidant, antibiotic).24 Phytochemical-based polyactives, reported by 
Lee et al., released vanillin from a linear polyoxalate backbone for antioxidant 
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properties.25-26 Similarly, Uhrich et al. demonstrated antioxidant and antimicrobial 
activities via the release of EDTA/phenolics (carvacrol, thymol, and eugenol)27 and 
pinosylvin28 from linear poly(anhydride esters).  These few examples illustrate the ability 
to effectively sequester phytochemicals as biodegradable polyactives with high loading 
(50 – 100 wt %) and sustained, tunable release profiles. 
1.5 Our approach 
The work highlighted in this dissertation focuses on the encapsulation, 
sequestration, and release of antimicrobial EO derivatives from thiol-ene networks. The 
second chapter of this dissertation provides a detailed review of how thiol-ene chemistry 
has been harnessed to design novel encapsulation/delivery platforms of model 
hydrophobic compounds. The third chapter demonstrates the direct encapsulation of 
phenolic phytochemicals (carvacrol and thymol) within thiol-ene nanoparticles for 
sustained delivery. Chapters 4 and 5 present a new paradigm for sequestration and release 
of EOs within phytochemical-derived polymer systems – an approach that draws 
inspiration from well-established “pro-drug” and “pro-fragrance” strategies employed 
successfully in pharma and cosmetic industries.29-30  We focus on the design of 
poly(thioether acetal) polymer networks in which aldehydes (e.g., anisaldehyde and 
chlorobenzaldehyde) are covalently incorporated into the polymer network via an acetal 
linkage – as an integral part of the polymer backbone.  These materials serve as pro-
antimicrobial networks (PANs) that release active antimicrobial aldehydes upon exposure 
to conditions conducive to acetal degradation (e.g., change in humidity/pH).  The PAN 
approach enables high loading, highly efficient “encapsulation”, solvent-free processing, 
and rational design of phytochemical release profiles. 
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CHAPTER II - UTILIZATION OF THIOL-ENE CHEMISTRY IN DRUG DELIVERY 
APPLICATIONS 
2.1 Thiol-ene “click” coupling/polymerization reactions 
Thiol-mediated polymerizations, including radical, base, and nucleophile 
catalyzed reactions, have emerged as valuable tools for the synthesis of a variety of 
functional materials.31-35 The thiol-mediated reactions are attractive for developing 
therapeutic delivery platforms since the reactions proceed under facile reaction conditions 
(oxygen, water, and room temperature), possess rapid kinetics in high yield, do not 
require expensive or potentially toxic catalysts, and are highly tolerant toward a wide 
range of functional groups.33 The use of thiol-mediated chemistries has enabled the 
formation of multiple therapeutic matrices exhibiting tunable release properties and 
triggered responses from external stimuli. In this introduction chapter, we will provide a 
brief overview of thiol-mediated reactions and their usage within controlled drug delivery 
– covering topics such as therapeutic encapsulation, prolonged release, and release of 
drugs from degradeable matrices. 
2.1.1 Radical-mediated thiol-ene photopolymerization 
The radical mediated thiol-ene reaction, which became popular after the 
pioneering work of Hoyle 36-38, Khan 39-40, and Bowman41-43, is the reaction of a thiol 
across an electron rich alkene in the presence of a radical initiator (thermal, photo, or 
redox). Thiol-ene networks form via a free-radical step-growth polymerization of 
multifunctional thiols and enes – facilitated by a rapid, highly efficient chain-transfer 
reaction as depicted in Figure 2A. The initiating species is often generated via hydrogen 
abstraction between a thiol and an activated initiator. The generated thiol radical then 
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adds across the double bond of an ene monomer generating a β-thioether carbon-centered 
radical; the latter radical rapidly undergoes chain transfer with an additional thiol to 
regenerate the thiol radical species. Termination then occurs via various recombination 
reactions.44 Typical thiols that are commonly encountered in radical mediated thiol-ene 
polymerizations include alkyl thiols, thiol propionates, thiol glycolates, and thiol phenols. 
For each thiol, electron rich terminal alkenes (vinyl ethers and allyl ethers) and strained 
alkenes (norbornene) react faster than electron defficient, internal, or substituted 
alkenes.33  In drug delivery applications, the use of thiol-ene photopolymerization is 
particularly attractive as it offers readily available biocompatible monomers with tunable 
polymerization kinetics simply by controlling intensity or photoinitiator type. 45-46 
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Figure 2.1 Different initiation mechanisms for thiol-ene reactions: (A) radical mediated, 
(B) base-catalyzed, and (C) nucleophile catalyzed. 
2.1.2 Base and nucleophile-catalyzed thiol-ene polymerization 
The base-catalyzed thiol-ene addition, or Michael addition, has found wide-spread 
utility as a mild reaction strategy in both organic and polymer “click” reactions owing to 
its high selectivity, rapid kinetics, and environmentally friendly reaction conditions (room 
temperature, oxygen/light tolerant, low catalyst levels).47 Specifically, the base-catalyzed 
Michael addition is an 1,4 addition which starts by deprotonation of a thiol by a sterically 
hindered base (e.g. triethylamine) (Figure 2.1B). The thiolate ion attacks the β-carbon of 
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an α,β-unsaturated carbonyl/sulfonyl resulting in a negatively charged enolate 
intermediate, which undergoes chain transfer via the protonated catalyst or other thiol to 
continue the process. The benefits of the thiol-Michael addtion (as mentioned previously) 
have been exploited in the synthesis of click hydrogels for theraputic delivery under 
aqueous conditions.48-49 
Unlike the base-catalyzed pathway, the nucleophile-catalyzed pathway involves 
direct reaction of a nucleophile (e.g. dimethylphenylphosphine) with an electron deficient 
alkene to generate a strong base (Figure 2.1C). The generated base abstracts a hydrogen 
from a thiol to form a thiolate anion which then follows the same addition and chain transfer 
reactions as described for the base-catalyzed mechanism. Due to the limited water 
solubility and high reactivity with metals and organic compounds, phosphine-catalyzed 
reactions have not been used in the fabrication of hydrogels for cell incapsulation or drug 
delivery.  For a detailed description of the effect of different initiators/catalysts, a thorough 
review on the advancements on thiol-Michael additions was published recently by 
Bowman and coworkers.47 
2.1.3 Thiol-ene step-growth vs. chain growth networks 
Thiol-ene monomers can undergo either a step-growth polymerization mechanism 
or a combination of step and chain growth polymerization. While parameters such as 
initator type, cure intensity, and oxygen tolerance are critical for curing monomer, it is 
the monomer structure (e.g. functional groups) and polymerization mechanism which 
dictate the final macromolecular architecture of the three-dimensional polymer network. 
It has been well established that networks formed via chain growth polymerization are 
heteregeneous (with regions of high localized crosslink density – interspersed between 
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regions of low crosslink density) due to the formation of different kinetic chain lengths, 
cycles, and dangling chain ends (Figure 2.2A).50 Importantly, the polymerization of 
multifunctional monomers such as acrylates, methacrylates, or styrenics, results in 
repeating -C–C- linkages along the backbone of the crosslinked network rendering the 
material nondegradable.51 Cleaveable linkages (ester, anhydride, acetal, ketal, etc.) can be 
installed within the crosslinker to promote network degradation. Unfortunately, due to  
chain growth network formation, the cleavage of the degradable linkages often leads to 
long linear polymer fragments which may trigger an immune response.52-56 
 
Figure 2.2 Differences between chain-growth (A) and step-growth (B) network 
formation. 
Alternatively, step-growth polymerization provides a superior method for the 
formation of a homogeneous network. Multifunctional monomers (f > 2) with different 
functional groups react in a stepwise fashion to form a crosslinked network with well 
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defined molecular weight between each crosslink junction. The mechanism of step-
growth polymerization ensures that any functionality (e.g. degradable linkages) in the 
monomer will be present within the crosslink junctions of the network (Figure 2.2B). For 
a step-growth network, exposure to a stimulus will trigger every crosslink junction to 
cleave allowing for complete network degradation into small molecule constituents as 
opposed to polymers/oligomers derived from chain-growth networks. 
 Specific to thiol-ene step-growth polymerizations, the alternating propagation 
and chain transfer events of the polymerization process proceed rapidly and build 
molecular weight in a uniform manner, but reach the gel-point only at relatively high 
functional group conversions yielding defect-free polymer networks.57 The homogeneity 
of the network is typically reflected by a narrow glass transition occurring over a range of 
30 – 50 °C. Recently, Kim et al. compared the degradation of acetal-based networks 
prepared via chain-growth (methacrylates) and step-growth (thiol-ene) polymerization.58  
Upon network hydrolysis, the methacrylate network remained intact (long linear polymer 
fragments did not degrade) while viscous flow was observed for the thiol-ene network 
due to complete degradation into small molecule byproducts.  
2.1.4 Drug delivery design via thiol-ene chemistry 
  Incorporation of a drug within a polymeric matrix can be classified into one of 
two strategies: 1) traditional delivery, which relies on dispersing the drug within a 
degradable or non-degradable polymeric matrix; and 2) poly(actives), in which the drug 
is polymerized directly into the polymer backbone or covalently tethered to the backbone 
(pendent) via degradable linkages (Table 2.1).  These delivery strategies offer different 
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release mechanisms, which can be governed by Fickian or non-Fickian diffusion, or a 
combination of both.   
Table 2.1 Thiol-ene based drug delivery platforms (potential and existing).  
Delivery platform Release Parameters Matrix Fate References 
Traditional delivery platforms 
Dispersed thermoplastic 
 
• Drug/polymer: 
crystallinity, solubility, and 
miscibility 
• Water permeability 
• Polymer MW and Tg 
Non-degradable 
No examples to 
date 
Dispersed thermoset 
 
• Drug/polymer: crosslink 
density, solubility, 
miscibility 
• Water permeability 
• Tg 
Non-degradable 
Lignin59, thio-
ether ester60 
Dispersed + degradable 
thermoplastic 
 
• Drug/polymer: 
crystallinity, solubility, 
miscibility 
• Water permeability 
• Polymer MW and Tg 
• Degradation rate of linker 
in the environment 
Degradable 
poly(thioether 
ester)61-62 
Dispersed + degradable 
thermoset 
 
• Drug/polymer: crosslink 
density, solubility, 
miscibility 
• Water permeability 
• Tg 
• Degradation rate of linker 
in the environment 
Degradable 
Anhydrides63-
64, orthoester65, 
chitosan-ester66 
Poly(actives) 
Covalently attached 
thermoplastic (pendent) 
 
• Drug/polymer: 
crystallinity, solubility, 
miscibility 
• Water permeability 
• Polymer MW and Tg 
• Degradation rate of linker 
in the environment 
Non-degradable 
No examples to 
date 
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In designing effective drug delivery platforms for specific applications – 
monomer selection, polymerization kinetics, incorporation of degradable/non-degradable 
linkages, drug hydrophilicity/phobicity, crosslink density, crystallinity, glass transition 
temperature (Tg), reaction byproducts and relevant degradation stimuli should be 
carefully considered. In this section, we will discuss the advantages and disadvantages of 
each strategy, followed by examples of drug delivery utilizing thiol-ene chemistry. 
2.1.5 Passive delivery 
Passive delivery relies on physically mixing/encapsulation of the drug within 
either a non-degradable or degradable polymer matrix (thermoset and thermoplastic), 
which mitigates the need of drug modification and improves the biostability and 
bioavailability - especially for hydrophobic drugs. Polymeric matrices can be inert, in 
Covalently 
attached 
thermoplastic 
(main chain) 
 
• Drug/polymer: 
crystallinity, solubility, 
miscibility 
• Water permeability 
• Polymer MW and Tg 
• Degradation rate of linker 
in the environment 
Degradable 
No examples to 
date 
Covalently attached 
thermoset 
 
• Drug/polymer: crosslink 
density, solubility, 
miscibility 
• Water permeability 
• Tg 
• Degradation rate of linker 
in the environment 
Non-degradable 
Disulfides and 
esters,67 
Active Networks 
 
• Drug/polymer: crosslink 
density, solubility, 
miscibility 
• Water permeability 
• Tg 
• Degradation rate of linker 
in the environment 
Degradable acetals68-69 
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which the matrix behaves as a membrane with constant drug release, or swellable, in 
which drug release is dependent on concentration gradients and degree of swellability.  
2.1.5.1 Thermoplastics 
Various non-degradable linear polymeric matrices such as poly(urethanes) and 
poly(dimethylsiloxanes) have been highlighted in the literature and have been widely 
used as drug-eluting medical implants; however, very few examples of drug eluting 
poly(thioethers) exist in literature.61-62 In general, the release profile of drugs dispersed in 
thermoplastics can be controlled via polymer molecular weight, crystallinity, 
hydrophilicity/phobicity, swellability, and the presence/absence of degradable linkages. 
Multiple papers have reported the synthesis of semicrystalline poly(thioethers) 
with tunable crystallinity through traditional emulsion polymerization techniques.70-71 
Additionally, direct incorporation of degradable esters and anhydrides have been 
demonstrated within semicrystalline poly(thioether) backbones.72-74 These degradable 
linkages allow the polymer chains to be broken down into di-acids and di-alcohols under 
mild conditions. For instance, Cardosa et al. have directly polymerized a di-alkene 
anhydride (1,3-propylene diundec-10-enoate) with 1,4-butanedithiol to yield degradable 
linear poly(thioether) with number average molecular weights ranging from 5-20 kDa.75 
These semicrystalline polymers have a melting temperature around 70 °C and exhibited 
no observable cytotoxicity toward red blood cells even at 200 µg L-1.  
Recently, Araújo and coworkers developed a linear poly(thioether ester) 
platform61-62 based on butanedithiol and a dialkene synthesized via an esterification 
reaction of 10-undecanoic acid with isosorbide. The monomers were polymerized via 
radical-initiated miniemulsion polymerization, resulting in semicrystalline polymers with 
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molecular weights ranging from 2-11 kDa.62 Coumarin 6, a hydrophobic dye, was 
encapsulated during the emulsification process with up to 98% efficiency and served as a 
visual marker for cellular uptake. The nanoparticles displayed no observable cytotoxicity 
at concentrations ranging from 10-200 µg mL-1 and are good candidates for a biomedical 
nanomaterial. Araújo expanded this platform with the encapsulation of clove oil within 
the poly(thioether ester) miniemulsion process.61 The nanoparticles obtained by 
miniemulsion polymerization were formulated with clove oil varying from 0 to 25% 
(w/w of monomer) with a ~98% encapsulation efficiency. The antioxidant, or radical 
scavenging properties of the nanoparticles with only 6% clove oil demonstrated potent 
antioxidant capabilities while preserving the bioactivity of the antioxidant rich clove oil 
constituents (e.g. eugenol). The ability to rapidly generate libraries of materials under 
facile reaction conditions necessitates future investigations into thiol-ene scaffolds as 
drug delivery matrices. While Cardosa and Araújo have highlighted the use of 
difunctional thiol and alkene monomers for direct preparation of linear poly(thioethers), 
additional studies are needed to translate the use of these polymers into clinical studies in 
vivo.  
2.1.5.2 Thermosets 
Tuning the degradation of and release from linear polymers remains a challenge 
as degradation/release rates are determined by manipulating coupled parameters such as 
drug/polymer crystallinity, drug/polymer molecular weight, polymer functionality, 
swellability, and drug/polymer hydropathy. Alternatively, crosslinked (thermoset) 
matrices offer unique opportunities to tailor the release of actives via manipulation of 
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defined parameters such as monomer functionality, crosslink density, monomer 
concentration, and monomer molecular weight.  
Two of the most commonly used crosslinked thiol-ene based drug delivery 
designs are hydrophilic (e.g. hydrogels) 76 and hydrophobic  (e.g. low molecular weight 
multifunctional thiols and alkenes) crosslinked networks77.  In a recent review by Kloxin 
et al., the design parameters for tuning the drug release from thiol-ene based hydrogels, 
such as tuning mesh size and swellability, are discussed.76 While hydrophilic networks 
primarily rely on swelling as a mechanism for drug release, hydrophobic thiol-ene 
networks depend on either the diffusivity of the drug through the matrix or degradation of 
cleavable linkages present within the backbone/side chain of the network. 
2.1.5.2.1 Non-degradable thermosets 
One key advantage to the direct encapsulation of drugs is that challenges such as 
hydrophobicity, volatility, and chemical instability can be easily overcome. Direct 
encapsulation via thiol-ene miniemulsion has recently been proven to be an effective 
encapsulation technique. Tong et al. used a miniemulsion to copolymerize an allyl-
functionalized-lignin with a multifunctional thiol in the presence of a hydrophobic dye (to 
monitor release), hexadecane (hydrophobe), solvent, surfactant, and water (continuous 
phase).59 The resulting nano-sized emulsions possessed high encapsulation efficiencies 
and were able to release 40% of the dye within 48 h at pH 7.4. These nanoparticles 
served as a primary example of utilizing materials found in nature for the controlled 
release of hydrophobic molecules such as drugs/dyes. Recently, Amato et al. 
demonstrated the direct sequestration of essential oil derivatives (carvacrol from oregano 
and thymol from thyme) into crosslinked poly(thioether) nanoparticles via miniemulsion 
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polymerization.60 The nanoparticles were loaded with relatively high efficiencies (>90%) 
and exhibited a constant drug release (<5%) over a 24 h period. The necessity of a 
hydrophobic matrix was pronounced, as high loadings, long-term delivery, and high 
encapsulation efficiencies of essential oils could not be readily attainable within a 
hydrogel.  
Additionally, Shi and coworkers synthesized micron-sized oil-in-water thiol-ene 
droplets for the sequestration of hydrophobic fragrance oils and dyes.78 The process 
showed a remarkable encapsulation efficiency (91-96%), rapid polymerization kinetics 
(<45 minutes) and the resulting capsules were relatively shelf-stable at 45°C for at least 
one month. Heating the microcapsules to 100 °C pressurized the capsules, induced 
rupture of the membrane, and subsequently released the fragrance. Emulsion focused 
crosslinked thiol-ene platforms highlight the utilities of applying fast reaction kinetics to 
rapidly encapsulate – and eventually release – hydrophobic drugs. However, these 
emulsion-based delivery platforms are complicated due to the multiple additives used 
during polymerization which can affect the release profile as well as biocompatibility. 
Additionally, the previously mentioned studies have yet to systematically vary 
parameters such as crosslink density (mesh size and Tg,), network hydrophobicity, or 
drug solubility to control drug release and these parameters should be studied in the 
future. 
2.1.5.2.2 Degradable Thermosets 
One of the most well-characterized hydrophobic drug delivery systems obtained 
by thiol-ene polymerization is the poly(anhydride), which has been popularized by Shipp 
et al.79 Photopolymerized poly(anhydride) thiol-ene networks have been shown to surface 
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erode as seen in other poly(anhydride) materials.80-81 The erosion process is due to the 
rate of anhydride degradation being faster than water ingress into the hydrophobic 
polymer matrix. Aside from the rate of anhydride hydrolysis, two synergistic parameters 
work together to limit water ingress: 1) high crosslink density achieved from low 
molecular weight – multifunctional monomers; and 2) monomer hydrophobicity (e.g., 
absence of alcohols, amines, carboxylic acids, etc. typically found in hydrogels). It is a 
common phenomenon within thiol-ene networks that as molecular weight between 
crosslinks increases, the free volume, hole-size, and diffusivity of molecules through the 
network increase.82 Additionally, reducing the number of hydrogen bond 
donors/acceptors within the polymer structure is known to limit the water uptake of the 
network and can therefore serve as another parameter to tune the release profile.  
Regarding direct polymerization of degradable poly(anhydrides), Shipp and 
coworkers synthesized a library of linear and crosslinked drug-loaded poly(thioether 
anhydrides) with varying degrees of hydrophilicity, hydrophobicity, and crosslink 
density.63 Shipp’s work highlighted that increasing the amount of tetrafunctional 
crosslinker resulted in a delayed onset of degradation. Other work from Shipp and 
coworkers involved the direct encapsulation of lidocaine within thiol-ene poly(anhydride) 
networks of varying crosslink density.64 Results from the study showed minimal 
differences in network degradation for networks prepared with 30, 20, and 10% 
crosslinker, indicating that erosion of the material plays a greater role in the release of 
lidocaine than drug diffusion out of the hydrophobic network.  
The encapsulation and controlled release of other hydrophobic drugs, such as 
doxorubicin and paclitaxel, are paramount because of the associated high toxicity and 
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limited pharmacokinetics of the drugs. Tang and coworkers successfully entrapped 
doxorubicin within a hydrophobic/degradable crosslinked thiol-ene poly(orthoester) via 
reaction-induced nanoprecipitation.65 During nanoprecipitation, doxorubicin was loaded 
into the nanogels with high drug loading efficiency greater than 70%. Release kinetics 
were performed at pH 7.4 and 5.0 to highlight the rapid degradation of the pH triggered 
hydrolysis of the orthoester. At pH 5.0, ~75% of doxorubicin was released within 24 h 
and at pH 7.4, ~15% was released. Cheng et al. also encapsulated doxorubicin via 
photopolymerization of N-maleoyl-functionalized chitosan and 1,4-butanediol 
bis(3mercaptopropionate) in miniemulsions.66 The crosslinked emulsified particles 
exhibited a doxorubicin encapsulation efficiency and loading level ranging from 76-82% 
and 5.6-6.1%, respectively. To demonstrate a pH directed release, the doxorubicin-loaded 
nanoemulsions were subjected to pH 7.4 and 5.5 – leading to ~30-40% and 55-80% 
release, respectively, within 48 h. Additionally, the results from cellular uptake studies 
suggested that the doxorubicin-loaded nanoparticles can serve as an extended/controlled 
release delivery platform in which the particles slowly release doxorubicin outside cells 
(pH 7.4) and release doxorubicin at higher concentrations when internalized in 
endosomes/lysosomes (pH 4.5-6.5).  
Other processing techniques, such as electrospinning, have also been used to 
encapsulate/release drugs from crosslinked thiol-ene networks. Heise et al.83 UV-cured 
electrospun crosslinked fibers, with poly(globalide), difunctional thiols (crosslinkers), 
photoinitiators, and indomethacin (an anti-inflammatory drug). The fibers could swell in 
organic solvents, such as dichloromethane (DCM), without dissolving, and were able to 
be loaded either by direct incorporation of indomethacin into the resin or swelling neat 
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fibers in concentrated indomethacin/DCM solutions. They found that the direct 
incorporation method led to linear release, proportional to fiber degradation, whereas the 
solvent swelled methods added physiosorbed drug to the surface – causing unwanted 
burst release followed by gradual and sustained release. 
2.1.5.2.3 Poly(active) thiol-ene materials 
Poly(actives) are polymeric pro-drugs that undergo partial or complete degradation to 
release active therapeutic agents (e.g., anti-inflammatory, antioxidant, antibiotic).84 Direct 
attachment of a drug to a poly(active) affords many unique advantages such as the 
alteration and control over the drug’s hydropathy, propensity to crystallize, 
pharmacokinetics, dissolution/release rate, and potential cytotoxicity. The linker between 
the drug and polymer scaffold can either be cleavable (pH, enzymatic cleavage, 
temperature, electromagnet radiation, etc.) or highly stable (amides, ethers, thio-ethers, 
etc.). For systems containing cleavable linkages, the rate of drug release is governed by 
both the linker chemistry (linker type and hydropathy) and environmental conditions . 
Additionally, the hydropathy and crosslink density of the polymer network in crosslinked 
poly(actives) or crystallinity in linear poly(actives) will play a significant role in linker 
degradation for processes such as hydrolysis and enzymatic degradation. Unlike 
traditional hydrogels in which hydrolysis events are statistical throughout the gel, 
hydrophobic networks must rely on the diffusion of water from the outside of the material 
towards the center – leading to a gradient of hydrolysis events through the material. 
 Shen and coworkers synthesized a crosslinked poly[oligo(ethylene 
glycol)fumarate-codithiodiethanol fumarate] micelle with a covalently attached 
doxorubicin.67 The system involved a hydrophobic fumarate, a PEG-diol, and a disulfide-
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diol, which creates linear hydrophilic/phobic domains interspersed between disulfides 
and esters allowing for both pH and reduction triggered degradation. The degradable 
poly[oligo(ethylene glycol)fumarate-codithiodiethanol fumarate] was crosslinked in 
water via a one pot addition of doxorubicin-SH (synthesized with a hydrolysable 
hydrazone linkage) and a dithiol crosslinker. During crosslinking, the system self-
assembles into a micelle in which the doxorubicin is covalently attached to the core at 
drug loading concentrations up to as high as 17.5 wt%. Importantly, when the crosslinked 
particles were placed into pH 7.4 water, only 5% of doxorubicin was released in 48 h, 
indicative of a high degree of covalent attachment of doxorubicin-SH during the 
crosslinking reaction. Under pH 7.4 and 10 mM dithiothreitol (a reducing environment to 
mimic the intracellular environment) only a 5% release of doxorubicin was observed.  
However, when the particles were subjected to pH 5.8 in the absence of dithiothreitol, 
~50% of doxorubicin was released in 48 h. This behavior suggests that the environmental 
pH controls the rate of hydrazone hydrolysis of the doxorubicin linkage not the scaffold 
degradation. The combination of dithiothreitol and a pH 5.8 environment resulted in 
~70% doxorubicin release and micelle disassociation. In this system, pH was the 
dominant factor in controlling doxorubicin release and serves as a model for how to 
design crosslinked-covalently linked poly(actives) for triggered release applications. 
 Recently, Amato et al. have published on the covalent ligation of two aldehydes, 
p-chlorobenzaldehyde68 and p-anisaldehyde69 into a poly(thioether acetal) network. Both 
examples relied on the conversion of the aldehyde into a difunctional alkene monomer, 
which was subsequently photopolymerized into a thiol-ene network. When the network 
was submerged into acidic environments, the networks rapidly degraded into small 
 21 
molecule constituents (tetrafunctional alcohol and aldehyde). Similar to Shen’s work67, 
the rate of acetal hydrolysis controlled the rate of aldehyde released and 100% release 
occurred when the material completely dissolved into solution. Currently, few examples 
exist of covalent attachment of drugs into hydrophobic thiol-ene networks; however, 
unique opportunities exist in high performance sustained release systems in which 
permanence is not a requirement. 
2.1.6 Conclusion 
Remarkable progress has been made in the design and characterization of 
controlled drug-releasing materials prepared via thiol-ene chemistry. Many examples 
presented in this introduction chapter have shown great promise in the delivery of model 
hydrophobic drugs; these systems provide formulations for the delivery of application 
specific cargo moving forward. However, multiple opportunities to tailor drug release 
within well-defined thiol-ene networks remain unexplored, including monomer design, 
crosslinker design, monomer functionality, crosslink density, hydrophobicity, and 
thermal mechanical properties. Additionally, precise control over the release of 
hydrophobic drugs from thiol-ene matrices remains a constant challenge that needs to be 
addressed. Finally, the remarkable functional group tolerance and plug-in-play nature of 
the thiol-ene monomers can lead to new fundamental network structure-drug release 
relationships within crosslinked hydrophobic thiol-ene networks. 
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CHAPTER III - DESTRUCTION OF OPPORTUNISTIC PATHOGENS VIA 
POLYMER NANOPARTICLE-MEDIATED RELEASE OF PLANT-BASED 
ANTIMICROBIAL PAYLOADS 
3.1 Abstract 
We report the synthesis of antimicrobial thymol/carvacrol-loaded polythioether 
nanoparticles (NPs) via a one-pot, solvent-free miniemulsion thiol-ene 
photopolymerization process.  The active antimicrobial agents, thymol and carvacrol, 
were employed as “solvents” for the thiol-ene monomer phase in the miniemulsion to 
enable facile high capacity loading (~50% w/w), excellent encapsulation efficiencies (> 
95%), and elimination of all postpolymerization purification processes.  The NPs serve as 
high capacity reservoirs for slow-release and delivery of thymol/carvacrol-combination 
payloads that exhibit inhibitory and bactericidal activity (> 99.9% kill efficiency at 24h) 
against gram-positive and gram-negative bacteria, including both saprophytic (Bacillus 
subtilis ATCC 6633 and Escherichia coli ATCC 25922) and pathogenic species 
(E. coli ATCC 43895, Staphylococcus aureus RN6390, and Burkholderia cenocepacia 
K56-2).  This report is among the first to demonstrate antimicrobial efficacy of essential 
oil-loaded nanoparticles against B. cenocepacia – an innately resistant opportunistic 
pathogen commonly associated with debilitating respiratory infections in cystic fibrosis.  
Although a model platform, these results point to promising pathways to particle-based 
delivery of plant-derived extracts for a range of antimicrobial applications, including 
active packaging materials, topical antiseptics, and innovative therapeutics. 
3.2 Introduction 
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Microbial threats, particularly multidrug-resistant (MDR) bacterial strains and 
other emerging pathogens, are greatly impacting public health, burdening healthcare 
systems, and have potential to disrupt socioeconomic infrastructures in both developing 
and industrialized nations.  In the United States alone, the Center for Disease Control 
estimates at least two million illnesses and 23,000 deaths are attributed to multidrug-
resistant bacterial infections each year. Annually, these cases account for approximately 
$20 billion in excess health care costs and up to $35 billion in lost productivity due to 
sick leave and hospitalizations.85  While Staphylococcus aureus and Pseudomonas 
aeruginosa tend to dominate the MDR discussion, other microorganisms, such as 
Burkholderia cepacia complex (Bcc), have emerged as opportunistic pathogens with 
significant clinical importance in persons with cystic fibrosis (CF).86  Pulmonary 
colonization with Burkholderia cenocepacia, the most common isolate of the 18 member 
Bcc, results in severe respiratory infections in persons with CF and is associated with 
high morbidity and mortality rates.87  Effective treatments for B. cenocepacia infections 
are rare, as these bacteria exhibit high intrinsic resistance to most antibiotics.88  In 
general, the MDR microbial threat extends far beyond the effect on humans, and 
additionally impacts animal agriculture and veterinary medicine.  The continuous 
emergence of MDR pathogens and scarcity of new antimicrobial drug scaffolds in the 
pharmaceutical discovery pipeline have led to growing interest in natural, plant-derived 
extracts as alternatives to synthetic antibiotics.21  In this direction, essential oils (EOs) – 
typically complex extracts from aromatic plants comprising mixtures of aldehydes, 
terpenes and phenols – are well known to exhibit broad spectrum biological and 
antimicrobial activity.89-90  With many EOs identified as “Generally Regarded as Safe” 
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(GRAS), these extracts have been actively explored and continue to garner interest as 
food preservatives and packaging constituents,91-92 textile fragrances,93 pesticides,94 and 
other antimicrobial therapeutic applications.12, 27, 95   
Monoterpene phenol isomers, carvacrol and thymol, are major constituents of 
EOs extracted from oregano, thyme, and other plants belonging to the Lamiaceae family.  
These isomers show antiviral, antifungal, and broad spectrum antibacterial properties 
against both gram-negative and gram-positive bacteria, including MDR and biofilm 
forming microorganisms.96-97  In one promising example, EO extracts containing 
carvacrol and thymol as primary constituents were shown to inhibit the growth of several 
environmental and clinical bacterial strains belonging to the B. cepacia complex.98  The 
broad spectrum of activity of these isomers has been attributed to multiple modes of 
toxicity; however, the primary site of toxicity is the cell membrane.97  In general, these 
hydrophobic isomers act by partitioning into the cytoplasmic membrane leading to 
increased permeability, depletion of proton gradients, and subsequent disruption of 
adenosine triphosphate (ATP) synthesis.  The collapse of the proton motive force and 
depletion of the ATP pool eventually lead to cell death. 
A major challenge for the practical application of carvacrol and thymol as 
antimicrobial agents stems from the hydrophobicity (poor water solubility), volatility, and 
instability of these EO constituents.  Poor water solubility, in particular, limits the 
bioavailability of these compounds and significantly lowers their biological and 
antimicrobial activity, whereas volatility is problematic for achieving sustained release 
and controlled delivery.  To address these challenges, a variety of approaches have been 
reported to encapsulate hydrophobic EO constituents as colloidal systems, including oil-
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in-water emulsions, microemulsions, and nanoemulsions; molecular inclusion complexes; 
lipid-based carriers (e.g. liposomes and solid lipid nanocapsules);99 and polymer-based 
carriers (e.g. films, micro/nanocapsules, and nanoparticles).20-21, 100  Polymer 
nanoparticles (PNPs) are advantageous in that they offer a highly flexible delivery 
platform for antimicrobial applications, where nanoparticle properties (e.g. morphology, 
bulk/surface composition, and size) are readily tunable using a variety of synthetic 
approaches.101-104  In turn, these tunable PNP properties dictate important features such as 
particle stability, surface interactions, and EO loading and release kinetics.  In this 
direction, researchers have successfully incorporated carvacrol, thymol, and other 
phenolic EO constituents into various PNP matrices (chitosan,105 poly(lactide-co-
glycolide)23, 106, methylcellulose,107 and zein108) via emulsification-evaporation,23, 106 
emulsification-solvent exchange,107 and nanoprecipitation108 methods.  While these 
examples demonstrate facile fabrication, encapsulation, and exhibit antimicrobial 
activity, many suffer several deficiencies such as low EO loading (i.e. 3% w/w carvacrol 
in chitosan matrix), poor EO encapsulation efficiencies (e.g. 14 – 31% carvacrol-in-water 
emulsion and ionic gelation of chitosan),109 use of organic solvents during encapsulation 
(acetone, ethanol, dichloromethane),23, 108 and burst release profiles of EO.23, 106   
Miniemulsion polymerization is ideally suited for encapsulation of hydrophobic 
payloads (e.g. lipophilic drugs, pigments, fragrances, inorganic nanomaterials, and 
polymers) with high loading and encapsulation efficiencies,110-112 but has received little 
attention for sequestration and delivery of essential oils – particularly towards 
antimicrobial applications.  Miniemulsion polymerizations are described as aqueous 
dispersions of small, narrowly distributed monomer droplets stabilized against Ostwald 
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ripening and collisional degradation by addition of an appropriate surfactant and 
costabilizer.    Monomer droplets ranging in size from 50-500 nm are attained via high 
shear mixing – typically either high-pressure homogenization or ultrasonic processing – 
and subsequently serve as discrete nanoreactors for the formation of polymer 
nanoparticles upon polymerization. Since mass transport between monomer droplets is 
suppressed, encapsulation of hydrophobic materials requires a straightforward addition of 
the desired material to the organic phase prior to shear mixing.  Thus, encapsulation of 
materials miscible with the monomer phase provides polymer nanoparticles with the 
payload dispersed throughout the polymer matrix (whereas immiscible materials provide 
a route to nanocapsules).112  Recently, we and others have reported thiol-ene113-116 and 
thiol-alkyne117-118 polymerization in miniemulsion as a facile platform for the synthesis of 
crosslinked polythioether nanoparticles with tunable particle sizes, tailorable network 
properties, and clickable surface functionality.  More importantly, we demonstrated the 
ability to encapsulate hydrophobic inorganic nanoparticles within the polythioether 
matrix with high efficiency without sacrificing the rapid polymerization kinetics and high 
conversions provided by the thiol-mediated photopolymerization process.   
Herein, we report a facile, one-pot approach to encapsulate monoterpene phenols 
(carvacrol/thymol) within polythioether nanoparticles as a model, sustained-release 
antimicrobial platform.  We employ thiol-ene photopolymerization in miniemulsion for 
rapid nanoparticle synthesis, where carvacrol and thymol serve as miscible 
compatibilizers in the monomer phase enabling solvent-free encapsulation with high 
loading capacities (33-66% w/w, EO relative to the NP) and excellent encapsulation 
efficiencies (> 95%).  The absence of solvent and use of a polymerizable surfactant 
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eliminate the need for any post-polymerization purification steps.  Release studies reveal 
the polythioether nanoparticles function as sustained-release reservoirs for 
carvacrol/thymol – discharging less than 4% of the payload over 24 h.  The 
thymol/carvacrol-loaded (TCNPs) nanoparticles show effective antimicrobial activity (> 
99.9% kill efficiency at 24h) against gram-positive (Bacillus subtilis and Staphylococcus 
aureus) and gram-negative (Escherichia coli and Burkholderia cenocepacia) bacteria.  
Considering the innate resistance of the bacterial strain, the high efficacy of TCNPs against 
Burkholderia cenocepacia is particularly significant, and to our knowledge, represents 
the first demonstration of antibacterial efficacy against B. cenocepacia using 
thymol/carvacrol-loaded polymer nanoparticles. 
3.3 Experimental 
3.3.1 Materials 
Glycol di(3-mercaptopropionate) (GDMP) and pentaerythritol tetra(3-
mercaptopropionate) (PETMP) were provided by Bruno Bock. Hexadecane, ethyl acetate, 
sodium chloride and thymol were obtained from Fisher Scientific. Diallyl phthalate 
(DAP), 4-methoxy phenol (MEHQ), and butyl acetate were acquired from Sigma 
Aldrich. Other reagents were purchased from the following vendors: 1-
hydroxycyclohexyl phenyl ketone (Irgacure 184) from CIBA; Hitenol BC-20 from 
Montello, Inc.; carvacrol from TCI America. Difco Agar, Mueller Hinton II agar (MHA), 
Mueller Hinton II broth (MHB), and Bacto Tryptone were from Becton, Dickinson and 
Company. All the materials were obtained at the highest purity available and used 
without further purification unless otherwise specified. 
3.3.2 Characterization Methods. 
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The size and distribution of the nanoparticles (NPs) were measured by dynamic 
light scattering (DLS) using a Microtrac Nanotrac Ultra NPA150 particle analyzer. 
Particle size and distribution were obtained using the Microtrac Flex software (v.10.6.1), 
which employs non-negatively constrained least-squares (NNLS) and cumulants analysis 
to obtain the intensity-weighted “z-average” mean particle size as the first cumulant, and 
the polydispersity index from the second cumulant.119 Transmission electron micrographs 
were taken with a Zeiss 900 electron microscope operating at 50 kV and outfitted with a 
Model 785 Erlangshen ES1000W CCD camera (Gatan). Samples were applied to 200 
mesh copper grids (3.05 mm, 200 lines per inch square mesh, EMS) coated with Formvar 
(5% polyvinyl formal resin). Proton (1H) NMR was recorded on a Bruker Acend™ 600 
MHz spectrometer at 30°C in D2O, using 128 scans and a 4.27 s relaxation delay. Optical 
density (OD) and fluorescence readings were performed in a BioTek Synergy 2 
programmable microplate reader. Confocal images were taken using a Zeiss LSM 510 
confocal laser scanning microscope. High-resolution field emission SEM (FE-SEM) was 
performed with a Zeiss SIGMA variable pressure field emission scanning electron 
Microscope operating at 10 kV in high vacuum mode. Samples were sputter coated with 
silver at instrument reported thickness of 5 nm with a Quorum Emitech K550X sputter 
coater. Raman spectra were acquired using a high-performance portable Raman 
spectrometer (i-Raman Plus, B&W Tek Inc., Delaware, USA). The samples were 
analyzed at 100 mW, with a 785 nm diode laser and 150 s accumulation time. 
3.3.3 General nanoparticle sample preparation. 
Each nanoparticle reaction was prepared in a 20 mL scintillation vial with a total 
volume of 10 mL. The organic stock solutions shown in Table A.1 were added into a vial 
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containing a stock solution of 70 mM Hitenol BC 20 and deionized water.  As we 
previously reported, MEHQ serves as a radical inhibitor to suppress thermal 
polymerization during ultrasonication.113 The samples were placed into an ice bath and 
sonicated using a Qsonica Q700 probe ultrasonicator at 25% amplitude for 25 min. The 
resultant miniemulsions were cured for 15 min at intensity of 185 mW cm−2 using an 
OmniCure S1000 UV light source with a 100W mercury lamp (λmax = 365 nm, 320–500 
nm filter). All samples were made in triplicate to ensure data reproducibility. 
3.3.4 Preparation of essential oil encapsulated nanoparticles. 
Carvacrol encapsulated nanoparticles were prepared by replacing butyl acetate 
with 33% w/w carvacrol as the solvent. For nanoparticles containing a combination of 
thymol and carvacrol, 20% w/w thymol was added along with 27% w/w carvacrol. The 
total organic fraction evaluated was 4.5% w/w for all samples. 
3.3.5 Determination of nanoparticle number density (particles/mL) 
added organictotalV  (1) 
Where organic added is a known volume that can be converted into cubic nanometers. 
 
Where r, is the radius (nm) determined from light scattering. 
particles
V
V
sphere
total #
 (3) 
The final # of particles is determined by dividing the total volume of organic by the 
volume of the average nanoparticle size (see Table A.2). This number results in 
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3
4
rVsphere    (2) 
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particles/10 mL (10 mL is the total volume of the emulsified solution), multiplication of 
volume added by this number results in # of particles delivered. 
3.3.6 Gas chromatography-mass spectrometry (GC-MS) release study of essentials 
oil nanoparticles. 
Freshly prepared CNPs and TCNPs were transferred into 100 mL volumetric flasks 
and diluted 1:10 with deionized water. For each diluted suspension, 10-mL aliquots were 
removed at 0, 4, 8, 12, and 24 h, and NPs were precipitated for 4 h at 40,000 rpm (4°C) in 
a Beckman Coulter Optima XE ultracentrifuge. 200 μL of the supernatant were removed 
and extracted by vortexing for 30 s with 800 μL of ethyl acetate. The liquid phases were 
separated by centrifugation for 15 min at 13,000 rpm, and the organic layer was 
transferred to a capped 1.5 mL GC-MS vial. To determine the amounts of EOs in the pre-
emulsified organic monomer mixture, 450 μL of organic stock solution (carvacrol and 
combo) was diluted 1:100 in ethyl acetate. All samples were placed into capped GC-MS 
vials and run using the following protocol. 
GC-MS analysis was performed on an Agilent 6890 GC/MSD equipped with an 
auto sampler and a Restek RTx-1 30 meter column.  All samples and standards were 
analyzed from 1 µL injection volumes.  Analysis parameters include an inlet temperature 
of 200 °C in splitless mode and a helium flow rate of 30 ml/min in gas saver mode. 
Thermal ramping conditions used include an initial hold at 45 °C for 4 min followed by 
an increase in temperature at 25 °C/ min. up to 140 °C with a 3 min hold at 140°C.  The 
temperature ramp continued at 2.5 °C/ min up to 150 °C with a 3 min hold followed by a 
final increase at 50 °C/min to 220 °C with a 7.00 min hold (Figure A8).  The method 
provided unique separation of thymol and carvacrol isomers eluting at 19.41 and 19.58 
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min respectively (Figure A9).  Calibration curves for both isomers were prepared in ethyl 
acetate at 0, 200, 400, 600, 800 and 1,000 ng µL-1 (Figure A10).  A representative 
chromatogram of extracted nanoparticles depicting the elution of thymol, carvacol and 
hexadecane can be seen in Figure A11. 
3.3.7 Evaluation of antibacterial activity of nanoparticles 
The antimicrobial activity of NPs was tested against several species of bacteria 
using a well diffusion method. The indicator microorganisms included 
Escherichia coli ATCC 25922 (serotype O6, biotype 1), E. coli ATCC 43895 (serotype 
O157:H7), Staphylococcus aureus RN6390,120 Bacillus subtilis 
subsp. spizizenii ATCC 6633, and Burkholderia cenocepacia K56-2 (clinical isolate from 
Canada)121. The testing was done on Mueller Hinton II agar (MHA) plates that have been 
overlaid with soft agar seeded with individual bacterial strains. The soft agar contained 
(per liter): 10 g of Bacto Tryptone, 6 g of Difco agar, and 8 g of sodium chloride. To 
create an overlay, the indicator organisms were grown overnight at 27°C (B. subtilis) or 
37°C (E. coli, S. aureus, and B. cenocepacia) in Mueller Hinton II broth (MHB). The 
overnight cultures were diluted 1:5 with fresh MHB, and mixed with molten soft agar to 
achieve the density of ~108 CFU mL−1. From this mixture, 4-mL aliquots were overlaid 
onto MHA base plates and allowed to completely solidify.  
After solidifying of soft agar, 8 mm wells were made, and their bottoms were 
sealed with 20 µL of MHA. Then, 70 μL of each sample were added to the wells and 
allowed to freely diffuse into growth medium. Wells containing pure carvacrol or a 
mixture of carvacrol (1 g) with thymol (0.6 g) were used as a positive control. Negative 
controls contained 70 mM Hitenol BC 20, or empty NPs suspended in butyl acetate. The 
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plates were incubated at each bacterium’s optimum growth temperature as listed above. 
The zones of inhibition (ZOI) were measured after 24, 48 and 72 h. Three replicates were 
carried out for each nanoparticle treatment and bacterial strain. Experiment was repeated 
three times to ensure data reproducibility. 
3.3.8 Determination of Minimum Inhibitory Concentrations (MICs) 
MICs of nanoparticles were determined using a modified broth microdilution 
method122. Briefly, overnight bacterial cultures were adjusted to ~105 CFU mL-1, and 
nanoparticles were serially diluted with sterile water to achieve a range of concentrations 
between 1011 to 107 particles µL-1. In a 96-well microplate, 150 µL aliquots of adjusted 
bacterial cultures were mixed with 50 µL aliquots of different NPs. Bacteria suspended in 
MHB without addition of nanoparticles served as a positive control, while MHB without 
bacterial inoculum and nanoparticles served as a negative control. The inoculated 
microplates were incubated at each bacterium’s optimum growth temperature, and the 
susceptibility of microorganisms to different NPs was assessed by measuring optical 
density at 600 nm. The results were expressed as % viability obtained through equation 4: 
  
Where OD is the optical density at 600 nm, t0 is the initial time 0 h, and t20 is the 
time after 20 h of incubation.  
For further verification of inhibition of bacterial growth, 10 µL of bacterial 
cultures treated for 20 h with different nanoparticles were plated on MHA and incubated 
at each bacterium’s optimum growth temperature for additional 20 h. The MIC refers to 
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the concentration of NPs that completely inhibited bacterial growth. Each treatment had 
four replications and experiment was repeated twice. 
3.3.9 Viability staining assays 
Bacterial viability was determined by using a LIVE/DEAD® BacLight™ Bacterial 
Viability Kit staining kit (Life Technologies). Overnight bacterial cultures were 
centrifuged at 8,500 rpm for 3 min, supernatants were removed and the bacterial cells 
were suspended in 0.9 % NaCl at OD600 of 0.1 (~10
8 CFU/mL). Freshly prepared 
nanoparticles were diluted 1:10 with sterile water. The adjusted bacterial cultures were 
mixed with the diluted nanoparticles at a ratio of 3:1, and incubated at 20°C in the dark. 
At 0, 2, 4, 6, 8, 12, and 24 h, 100 µL aliquots of the bacteria-NP mixtures were 
transferred into a black flat bottom microplate, and mixed with 100 µL of the 
LIVE/DEAD BacLight staining reagent. The samples were incubated in the dark for 
15 min, and fluorescence was measured using a 485/20 nm excitation filter (for both 
SYTO9 and PI) and a 528/20 nm (SYTO9 emission wavelength) and a 620/40 nm (PI 
emission wavelength) emission filter. For confocal imaging, 5 µL of the stained sample 
were cast on a microscope slide. Each sample was assayed in triplicate, and the 
experiment was repeated twice. The results of viability staining were confirmed by 
plating 10 µL of each bacterial suspension on MHA, and incubating the plates at an 
appropriate growth temperature for 20 h. 
3.3.10 Terminal dilution assays 
To compare the rate of bacterial killing by different NPs, the test organisms were exposed 
to NPs and the decline in numbers of viable bacteria was followed by a modified terminal 
dilution method.123 The bacterial cultures were prepared and adjusted to ~108 CFU mL-1 
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as described above. The adjusted bacterial cultures (9 mL) were mixed with nanoparticles 
(1 mL), and the bacterial populations were determined immediately after the addition of 
NPs (0 h), and at 2, 4, 8, 12 and 24 h of exposure. At each time point, 100-µL aliquots of 
the bacteria-NP suspensions were transferred into 96-well microplates prefilled with 200 
µL of MHB and serially diluted. The inoculated microplates were incubated for 48 h at 
appropriate growth temperature, after which the turbidity in each well was measured with 
a BioTek Synergy 2 microplate reader. An optical density at 600 nm of  0.05 was 
considered positive for bacterial growth. Populations of viable bacteria were calculated 
from the final dilution (terminal dilution, or TD), in which bacterial growth was observed 
using equation 5:  
CFU
mL
=
10×3TD
1mL
 (5) 
Where TD is the terminal dilution factor obtained from microplate readings.  
 
3.4 Results and Discussion 
3.4.1 Synthesis and characterization of essential oil encapsulated nanoparticles 
Polythioether NPs loaded with various ratios of carvacrol/thymol were synthesized 
via thiol-ene photopolymerization in miniemulsion according to Figure 3.1a.  NPs were 
prepared by dispersing the organic phase, comprising diallyl phthalate (DAP), glycol di(3-
mercaptopropionate) (GDMP), pentaerythritol tetra(3-mercaptopropionate) (PETMP), and 
carvacrol/thymol, into deionized water containing surfactant via probe ultrasonication for 
25 min (Figure 3.1b).  The full details for the miniemulsion formulation are given in Table 
S1.  The monomer droplets were then photopolymerized by exposure to UV light (λmax 
365nm). Control NPs (without carvacrol/thymol) were similarly prepared using butyl 
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acetate as a diluent for the organic phase.  After ultrasonication and photopolymerization, 
aliquots were removed and analyzed via 1H NMR (Figure A.1) in D2O. The disappearance 
of the peaks attributed to the thiol (–CH2CH2–SH, 2.62-2.83 ppm) and alkene (5.07-5.45, 
5.87-6.10 ppm) from the monomers, and broadening of other peaks indicated the thiol-ene 
photopolymerization proceeded to high conversion. Additionally, Raman spectroscopy of 
freshly emulsified nanoparticles prior to and after UV polymerization showed the 
disappearance of SH (2580 cm-1) and alkene stretches (1640-1680 cm-1) (Figure A.2).   The 
ability to achieve high thiol-ene monomer conversion in the presence of phenolic 
functional groups is in good agreement with our previous work.117, 124-125  At near 
quantitative conversions, crosslink density (0.168×10-3 mol/cm3) of the polythioether NPs 
was estimated from the rubbery plateau storage modulus (1.25 MPa, Tg -12.1 °C, Figure 
A.3) of the base thiol-ene resin (i.e. GDMP+PETMP+diallyl phthalate prepared at identical 
stoichiometric ratios used in the miniemulsions) at Tg + 40 °C according to the theory of 
rubber elasticity.126  To eliminate surfactant leaching, Hitenol BC-20 was employed as a 
polymerizable surfactant to covalently incorporate the surfactant into the thiol-ene network 
(discussed further in the antimicrobial section).  A series of exploratory NP syntheses were 
conducted, in which the concentration of Hitenol BC-20 (Figure A.4a) and organic weight 
fraction (Figure A.4b) were independently varied, to identify conditions to provide 
acceptable NP size and size distributions.  A 4.5 wt.% organic phase and 70 mM Hitenol 
BC-20 were identified as optimum parameters; these conditions provided pure carvacrol-
loaded NPs (CNPs), thymol/carvacrol-loaded NPs (TCNPs), and control NPs with mean 
particle sizes of 148 ± 24 nm (PDI: 0.560), 147 ± 19 nm (PDI: 0.387), and 183 ± 19 nm 
(PDI: 0.473), respectively, as determined by DLS (Figure A.3).  We note that the reported 
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std. dev. values represent the deviation in the average particle size obtained from a 
minimum of three separate syntheses.  A representative transmission electron microscopy 
(TEM) image for TCNPs loaded with a 0.75:1 T/C ratio (Figure 3.1c) showed spherical 
particles with sizes in good agreement with DLS analysis.  TEM for the control NPs and 
CNPs are shown in Figure A.5a and A.5b, respectively. The salient feature of this synthetic 
approach is that the carvacrol/thymol constituents serve as the “solvent” for the organic 
phase in the miniemulsion process.  This route enabled a high loading capacity of 
thymol/carvacrol within the NPs (between 33 – 66% w/w, EO/NP) with high encapsulation 
efficiencies (>95% by GC-MS), eliminated the need for an organic solvent during NP 
synthesis, and provided a one-pot approach to EO encapsulation without any post-
polymerization purification processes (e.g. no freeze drying, evaporation, extraction 
processes were required).  Thus, the NP dispersions obtained from the previously described 
synthetic approach were used directly for the antimicrobial studies detailed below. 
 
Figure 3.1 (A) The thiol-ene reaction involves alternating chain transfer and propagation 
(B) with various multifunctional monomers used to generate polythioether nanoparticles 
via thiol-alkene photopolymerization in miniemulsion. (C) Representative TEM of 
thymol/carvacrol-loaded nanoparticles. 
3.4.2 Loading and Release of Thymol and Carvacrol 
 37 
Next, we investigated the release kinetics of carvacrol and carvacrol/thymol 
mixtures released from polythioether NPs into water.  The amount of essential oil released 
was quantified by measuring the concentration of carvacrol/thymol available in water via 
GC-MS at 0, 4, 8, and 12 h. Figure 3.2a shows the release data for CNPs (synthesized at 
33% w/w C/NP) and TCNPs (synthesized with 47% w/w TC/NP, 0.75:1 T:C).  The EOload 
data points represent the total amount of carvacrol (16 ± 0.7 mg/mL) and thymol/carvacrol 
(25 ± 5 mg/mL)  loaded into the NPs during miniemulsion photopolymerization, and are 
in good agreement with initial formulations for each type of NP.  The ratio of the time 0 
and EOload concentrations represents the encapsulation efficiency for the miniemulsion 
process, i.e. ~96.9% for TCNPs and 96.8% for CNPs.  Thus, the concentration of EO within 
the nanoparticles is up to 20 times higher than the reported solubility limits for thymol 
(0.85 mg/mL) and carvacrol (1.25 mg/mL) at 20 °C.127  As shown in Figure 3.2a, the 
concentration of EO released from the NPs in water was relatively constant over 24 h, 
where TCNPs and CNPs reached plateau concentrations between 0.7-0.9 mg/mL and 0.5–0.6 
mg/mL, respectively.   These concentrations correspond to less than 4% release of the total 
EO payload over 24 h, (Figure 3.2b) and approach the solubility limit of thymol and 
carvacrol in water at 20 °C. These results suggest that the polythioether nanoparticles 
effectively serve as a reservoir for the hydrophobic carvacrol and thymol compounds.  This 
“reservoir effect” enables extended delivery of EO constituents into the bulk aqueous 
phase, where the solubility limit of the relatively insoluble compounds ultimately dictates 
the aqueous-phase equilibrium concentration.   
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Figure 3.2 (a) Amounts of essential oils extracted from the supernatant after pelleting 
NPs by ultracentrifugation. (b) Calculated release profiles for both CNPs and TCNPs over 
24 h. 
3.4.3 Antimicrobial properties 
Antimicrobial activity of the EO-containing NPs was evaluated against a panel of gram-
positive and gram-negative bacteria that included both saprophytic (B. subtilis ATCC 6633 
and E. coli ATCC 25922) and pathogenic species (E. coli ATCC 43895 [serotype 
O157:H7], S. aureus RN6390, and B. cenocepacia K56-2).  Our preliminary experiments 
revealed that control NPs prepared using either sodium dodecyl sulfate or 
cetyltrimethylammonium bromide as surfactant exhibited antimicrobial activity, 
presumably due to surfactant leaching. Thus, we chose Hitenol BC-20 – a commercially 
available polymerizable surfactant – for further experiments, as it exhibited no measurable 
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antimicrobial activity in zone of inhibition (ZOI) experiments at the concentration used in 
NP synthesis (70 mM Figure 3.3a; 140 mM Figure A.6). More importantly, control NPs 
prepared with Hitenol BC-20 showed no measureable ZOI against all five bacteria (Figure 
3.3b). 
 
Figure 3.3 Well diffusion assay identifies treatments with antimicrobial activity. Bacteria 
were incubated with 70 mM Hitenol BC-20 (a), ControlNPs (b), CNPs (c), and TCNPs (d) at 
1013 NPs mL-1. Zones of inhibition (ZOI, mm) are reported below each image. 
Initially, we evaluated the antimicrobial activity of NPs containing pure carvacrol 
(33% w/w, carvacrol relative to NP) and various ratios of thymol:carvacrol (Treatment I – 
66% w/w, 3:1 T:C; Treatment II – 55% w/w, 1.5:1 T:C; and Treatment III – 47% w/w, 
0.75:1) against E. coli ATCC 25922, S. aureus RN6390, and B. subtilis ATCC 6633 
(Figure A.7).  Since thymol is a solid at room temperature (mp 49-51 °C), thymol-loaded 
NPs were difficult to synthesize using a solvent-free approach and were not actively 
pursued in this work.  Previous reports have shown that combinations of thymol and 
carvacrol exhibit higher antimicrobial activity than each individual constituent,97 thus, 
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carvacrol-loaded NPs were evaluated via ZOI only as a comparison to NPs loaded with 
combinations of  thymol/carvacrol.  Interestingly, all treatments with NPs  containing 
thymol/carvacrol showed similar zones of inhibition (Figure A.7), thus treatment III, with 
the lowest overall thymol/carvacrol loading, was chosen for the experiments discussed 
hereafter.  From this point forward, the acronym TCNP will refer to nanoparticles loaded 
with 47% w/w, 0.75:1 T:C (treatment III).  Figure 3.3c and 3.3d show the results of well 
diffusion assays for CNPs and TCNPs against the full panel of bacteria.  As shown in Figure 
3.3c, CNPs exhibited moderate activity against all bacteria (ZOI 1 – 2 mm).  As expected, 
TCNPs were consistently more effective than CNPs, as indicated by the larger ZOIs shown in 
Figure 3.3d. TCNPs inhibited the growth of all five bacteria, including S. aureus (2 mm 
ZOI) and B. cenocepacia (3 mm ZOI) that are known to exhibit high intrinsic resistance to 
conventional antibiotics. Bacillus subtilis (6 mm ZOI) was the most susceptible species to 
the TCNP treatment. 
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Figure 3.4 Percent viability of various bacteria upon treatment with TCNPs. Inset images 
show the corresponding spot tests for the presence of live bacteria. 
The antimicrobial activity of TCNPs was further evaluated via determination of the 
minimum inhibitory concentration (MIC).  The MIC is defined as the lowest concentration 
of an antimicrobial agent that inhibits the growth of a microorganism following an 
overnight incubation period.  We adopted a modified broth microdilution method to 
determine MICs for NP-loaded thymol/carvacrol.122  We also spot-plated bacteria that were 
incubated with NPs to check for possible bacteriostatic effects.  While MIC assays are 
reputable for accuracy and standardized comparison across numerous antibiotics, the 
conventional MIC output presents a challenge for hydrophobic antibiotics encapsulated in 
polymer nanoparticles – and is particularly problematic for NP delivery systems that 
function via the “reservoir effect”.  As a result of the “reservoir effect”, the concentration 
loaded in the nanoparticle may be orders of magnitude greater than the concentration 
delivered to the bacteria during the timeframe of the MIC assay.  For example, the loaded 
concentration of thymol/carvacrol in TCNPs was determined to be 25,000 μg/mL by GC-
MS.  These thymol/carvacrol loading levels are up to 100-fold higher than reported MIC 
values for E. coli 25922 (MICcarvacrol: 225 μg/mL, MICthymol: 225μg/mL) and S. aureus 
(MICcarvacrol: 450 μg/mL, MICthymol: 225 μg/mL);128 however, our release studies show that 
carvacrol and thymol are delivered to the bulk aqueous phase at a relatively constant 
concentration of 500 – 900 μg/mL over 24 h. Following the precedent of Langer et al.,129 
who previously noted the difficulty in defining the MIC for antibiotic-loaded nanoparticles, 
we report concentrations as the total EO concentration within the NP at the beginning of 
the treatment to identify the MIC.  While the loaded concentrations grossly overestimate 
the MIC value relative to a conventional definition, we reasoned this route of reporting was 
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the most useful and conservative measure of NP-loaded antimicrobial efficacy. 
Additionally, we calculated the nanoparticle number density (#particles/mL) to estimate 
the number of NPs delivered in each experiment as an alternate MIC output value, with the 
caveat that the number density is based on the average particle diameter of a polydisperse 
nanoparticle population.  Nonetheless, number density MIC provides a point of comparison 
among the various bacteria investigated in this paper.  Figure 3.4 shows the results from 
the viability assays used to determine the MICs for TCNPs.  In general, the growth of all 
five bacteria included in this study was completely inhibited upon exposure to TCNPs loaded 
at 25,000 μg/mL (1010 nanoparticles) in a 50 µL broth volume, which translated to 
approximately 105 NPs per bacterial cell. B. subtilis was the most susceptible species, and 
was completely inhibited at TCNPs loaded at 2,500 μg/mL (109 nanoparticles, ~104 NPs per 
cell).  The MIC values are in good agreement with the previously described results of agar 
well diffusion tests. 
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Figure 3.5 Effect of TCNPs on the viability of (a) B. subtilis ATCC 6633 and (b) E. coli 
ATCC 25922, as monitored by confocal laser scanning microscopy. Representative 
images of control cultures (top row), and cultures treated with 1011 TCNPs (middle and 
bottom row) at the indicated time points. The green signal (SYTO 9) indicates viable live 
cells, whereas red signal (propidium iodide) indicates damaged or dead cells.  Scale bars 
= 10 µm. 
We also investigated the kill kinetics for the panel of bacteria incubated with TCNPs 
using live/dead and terminal dilution assays. Initially, the kill kinetics of TCNPs against B. 
subtilis ATCC 6633 and E. coli ATCC 25922 were probed using a live/dead cell viability 
assay, which stains “dead” bacteria red upon cell membrane damage and uptake of 
propidium iodide.  As shown in Figure 3.5a and 3.5b, a large number of viable bacterial 
cells (stained green) were observed for the B. subtilis and E. coli control samples, 
respectively.  Incubation of TCNPs with B. subtilis for 15 min yielded an apparent 50:50 
live/dead ratio, whereas 30 min resulted in mostly dead bacteria (Figure 3.5a).  For 
E. coli ATCC 25922, the 50:50 live/dead ratio was observed after two hours of incubation 
with TCNPs, and most bacteria stained dead after 8 h of incubation (Figure 3.5b).  To 
quantify the kill kinetics for all five bacteria, we used a terminal dilution assay.  Figure 
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3.6a shows the log reduction in the bacteria count as a function of incubation time with 
~1011 TCNPs.  The log CFU reductions at 48 h are reported as % kill values in Figure 3.6b.  
In agreement with our previous ZOI data, B. subtilis ATCC 6633 showed the highest 
susceptibility to the TCNP treatment with 4.3 and 7.1 log reductions observed at 12 and 24 
h, respectively. The log reductions for E. coli O157:H7 (ATCC 43895) were 3.5 at 12 h 
and 7 at 24 h – results that translate into a kill efficacy of > 99.99%. The viability of E. coli 
ATCC 25922 declined at a slower rate than E. coli O157:H7, however, the 48-hour 
exposure to TCNPs ultimately killed > 99.99% of the bacteria.   Incubation of TCNPs with B. 
cenocepacia K56-2 produced 3.9 and 6.2 log reductions at 12 and 24 h, respectively. The 
kill kinetics and high susceptibility (over 99.99% efficacy at 24 h) of B. cenocepacia to the 
TCNPs is of particular interest, as these bacteria have very high innate resistance to a wide 
range of antibiotics and biocides.130  With a 3.6 log reduction, S. aureus RN6390 was the 
only species that maintained viability after 24 h incubation with TCNPs.  However, a 6.3 
log reduction, or > 99.99 % kill efficacy for S. aureus was ultimately attained at 48 h.  
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Figure 3.6 Evaluation of antimicrobial activity for 1011 TCNPs/mL on the viability of 
() E. coli ATCC 25922, () S. aureus RN6390, () B. subtilis ATCC 6633, () E. 
coli ATCC 43895 (serotype O157:H7), and () B. cenocepacia K56-2 via (a) a kinetic 
terminal dilution and (b) percentage of bacteria killed and over 48 h. *Dashed line 
represents the limit of quantitation. 
Finally, insight into the antimicrobial mechanism was investigated by visualizing 
the microbial structure of B. subtilis ATCC 6633 and E. coli ATCC 25922 before and after 
prolonged contact with TCNPs using electron microscopy. Prior to exposure to TCNPs, TEM 
of both microbes showed intact cell structure (Figure 3.7, control).  After exposure with 
TCNPs, distinct indication of damage to the cell envelope (diffuse membrane, cellular 
debris) and loss of flagella were visible in both E. coli ATCC 25922 (Figure 3.7a) and B. 
subtilis ATCC 6633 (Figure 3.7b).  Additionally, the scanning electron microscopy (SEM) 
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image of B. subtilis after 24 h exposure to inhibitory concentrations of TCNPs showed 
bacteria with crumpled cell envelopes and pore-like lesions, which is consistent with the 
collapse of the cell structure (Figure 3.7c). These results are consistent with previously 
reported postulates that identify the cell membrane as the primary site of toxicity for 
carvacrol/thymol.97 
 
Figure 3.7 (a) TEM of E. coli ATCC 25922 and (b) B. subtilis ATCC 6633 control 
cultures and cultures that were challenged with 1011 TCNPs for various times. (c) High 
resolution SEM of the control culture of B. subtilis ATCC 6633 and the culture treated 
for 24 h with 1011 TCNPs. 
3.5 Conclusions 
ControlControl
(b) B. subtilis ATCC 6633(a) E. coli ATCC 25922
1 h2 h
2 h8 h
1 µm 1 µm
(c) B. subtilis ATCC 6633
Control 24 h
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We have reported a one-pot, solvent-free miniemulsion photopolymerization process for 
the synthesis of thymol/carvacrol-loaded polythioether nanoparticles.  Using the 
thymol/carvacrol payload directly as a diluent for the monomer phase in the presence of a 
polymerizable surfactant provided the active NPs without any post-synthetic purification.  
The NPs serve as high capacity reservoirs for slow-release and delivery of 
thymol/carvacrol-combination payloads that exhibit inhibitory and bactericidal activity (> 
99.9% kill efficiency at 24h) against gram-positive (Bacillus subtilis and Staphylococcus 
aureus) and gram-negative (Escherichia coli and Burkholderia cenocepacia) bacteria.  The 
simplicity, modularity, and efficacy of the essential oil encapsulation platform may combat 
bacteria with intrinsic resistance to conventional antibiotics, and is potentially adaptable 
for delivery of EOs as active packaging materials and topical antiseptics.  The antimicrobial 
activity of TCNPs against inherently resistant Burkholderia cenocepacia may provide a 
route to innovative pulmonary therapeutics by appropriately engineering the nanoparticle 
properties; investigations of thymol/carvacrol-loaded NPs against B. cepacia complex 
biofilms – a challenging form of the bacteria commonly associated with cystic fibrosis – 
are currently underway.  In this direction, we are particularly interested to exploit the 
simple synthetic modularity of this process for the design of EO-loaded biodegradable 
nanoparticles with specific surface chemistries to serve as multimode (e.g. contact biocidal, 
targeted NP-bacteria interactions) antimicrobial platforms. 
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CHAPTER IV - PRO-ANTIMICROBIAL NETWORKS VIA DEGRADABLE 
ACETALS (PANDAS) USING THIOL-ENE PHOTOPOLYMERIZATION 
4.1 Abstract 
We describe the synthesis of pro-antimicrobial networks via degradable acetals 
(PANDAs) as a new paradigm for sequestration and triggered release of volatile, 
bioactive aldehydes. PANDAs derived from diallyl p-chlorobenzaldehyde acetal degrade 
and release p-chlorobenzaldehyde as an antibacterial and antifungal agent under mild 
conditions (pH 7.4/high humidity).  We show that PANDAs enable facile access to 
materials with tunable release profiles, potent antimicrobial activity without triggering 
antimicrobial resistance, and minimal cytotoxicity. 
4.2 Introduction 
With 700,000 annual deaths globally, antimicrobial resistance is an escalating 
crisis that threatens the sustainability of public health and agricultural ecosystems.131 As 
the effectiveness of antibiotics has precipitously declined, a growing interest in 
alternative antibiotic scaffolds has proliferated.  In this direction, aromatic terpene 
aldehydes – major phytochemical constituents of plant derived essential oils (EOs) − are 
known to exhibit potent and broad spectrum antibacterial and antifungal activities in both 
liquid and gaseous states.132-133  However, practical application of terpenes remains a 
challenge stemming from their poor water solubility, volatility, and chemical instability.  
Many strategies have been reported to sequester or encapsulate terpenes within films or 
colloidal systems;134-135 however, these strategies often suffer deficiencies such as low 
loading, poor encapsulation efficiencies, necessity of organic processing solvents, and 
uncontrolled burst release profiles.136  
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“Polyactives” − polymeric pro-drugs that undergo degradation to release active 
therapeutic agents − address the deficiencies in sequestering EO constituents by 
providing high loading, chemical stability, and tailored release kinetics.84 Recently, linear 
polyactives of phytochemicals and other synthetic analogs have been used for the 
extended delivery of antimicrobials,27, 137 antioxidants,26, 138 anti-inflammatories,25 
hormones,139 and anti-cancer therapeutics.140-141 While successfully demonstrated, tuning 
the degradation of linear polyactives remains a challenge as degradation rates are 
determined by manipulating coupled parameters such as crystallinity, polymer molecular 
weight, functionality, and hydropathy.142 Alternatively, crosslinked polyactives (i.e. 
thermosets) offer unique opportunities to tailor release profiles by simple manipulation of 
crosslink density, monomer concentration, or monomer molecular weight.143 Recently, 
Matras and Chatterjee developed biodegradable crosslinked polyactive esters that 
challenge the performance of traditional linear polymers by offering greater control over 
degradation rates, mechanical properties, and release kinetics.144 Although these 
crosslinked polyesters showed high biocompatibility and are capable of releasing 
anticancer, anti-inflammatory, or antimicrobial compounds,145-147 the lengthy 
polymerization times (>1 day) at elevated temperatures (>130 °C) preclude 
polymerization in the presence of cells, in vivo, or in 3D printing applications. 
Furthermore, polyesters with sustained degradation typically exhibit localized 
accumulation of acidic byproducts leading to inflammatory response.148 Polyactive 
acetals are promising alternatives as acetals readily hydrolyze under mild aqueous 
conditions into pH neutral byproducts (alcohols and aldehydes).149 
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Inspired by polyacetal hydrogels,150-151 the work herein describes the synthesis of 
pro-antimicrobial networks via degradable acetals (PANDAs) derived from p-
chlorobenzaldehyde (pCB) using thiol-ene photopolymerization – an approach designed 
to address many of the aforementioned challenges with sequestration of terpene 
aldehydes.  Thiol-ene photopolymerization offers rapid cure kinetics at room 
temperature, low oxygen inhibition, homogeneous network formation, and high monomer 
conversion.152 Thiol-ene – as a step-addition polymerization –  ensures that nearly every 
crosslink junction contains a degradable, pCB-derived acetal. Therefore, PANDAs are 
molecularly designed to undergo complete degradation upon hydrolysis resulting in the 
release of pCB as an active antimicrobial and antifungal agent, and the generation of 
inactive low molecular weight degradation byproducts (Figure 4.1). 
 
Figure 4.1 Synthesis of PANDAs and major degradation byproducts. 
4.3 Experimental 
4.3.1 Materials 
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Allyl alcohol, triethylamine (TEA), 4-chlorobenzaldehyde (pCB), 1,3,5-triallyl-
1,3,5-triazine-2,4,6 (1H, 3H, 5H) trione (TTT), 2-hydroxy-2-methyl-1-phenyl-propan-1-
one (Darocure 1173), p-toluenesulfonic acid (pTSOH), molecular sieves (3Å), dry 
tetrahydrofuran (THF), hexane and ethyl acetate were acquired from Fisher Scientific. 
Pentaerythritol tetra(3-mercaptopropionate) (PETMP) was provided by Bruno Bock. 
Difco Agar, Mueller Hinton II agar (MHA), Mueller Hinton II broth (MHB), and Bacto 
Tryptone were from Becton, Dickinson and Company. All the materials were obtained at 
the highest purity available and used without further purification unless otherwise 
specified.  
4.3.2 Characterization Methods. 
1H NMR was recorded on a Varian Mercury Plus 300 MHz NMR spectrometer in 
chloroform-d. Dynamic mechanical analysis (DMA) was performed using a TA 
Instruments Q800 dynamic mechanical analyzer in tension mode equipped with a gas 
cooling accessory. Samples were clamped and tested at a strain of 1 %. Samples were 
heated from -80 °C to 90 °C at a ramp rate of 3 °C min-1. Kinetic data were obtained 
using real-time FTIR (RT-FTIR) spectroscopy by determining the conversions of the 
thiol and ene functional groups. The RT-FTIR studies were conducted using a Nicolet 
8700 FTIR spectrometer with a KBr beam splitter and a MCT/A detector with a 320–500 
nm filtered ultraviolet light source. Each sample was exposed to a UV light with an 
intensity of 200 mW cm-2. Series scans were recorded, where spectra were taken 
approximately 2 scan/s with a resolution of 4 cm-1. Thiol conversions was monitored with 
integrating the SH conversion peak between 2500-2620 cm-1 while the conversion of the 
allyl group was monitored with conversion peak between 3050-3125 cm-1. Optical 
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density (OD) and fluorescence readings were performed in a BioTek Synergy 2 
programmable microplate reader. 
4.3.3 Synthesis of p-chlorobenzaldehyde diallylacetal (pCBA) 
pCB (10 g, 71.14 mmol, 1 equiv), pTSOH (4.3 g, 24.97 mmol, 0.35 equiv), 3Å 
molecular sieves (15 g), and allyl alcohol (16.52 g, 284.6 mmol, 4 equiv) were dissolved 
in dry THF (50 mL). The yellow reaction mixture was left to stir overnight and then 
quenched with addition of TEA (19.8 mL, 142.3 mmol, 2 equiv), filtered and rotovapped 
before adding to a silica gel column. The column was eluted with a 10:90 (v:v) ethyl 
acetate/hexane mixture to afford 8.3 g (48.9%) of the acetal. 1H NMR (300 MHz, 
Chloroform-d) δ 7.46 (d, J = 8.4 Hz, 1H), 7.36 (d, J = 8.4 Hz, 1H), 5.95 (ddt, J = 16.2, 
10.8, 5.6 Hz, 1H), 5.63 (d, J = 2.7 Hz, 1H), 5.33 (dt, J = 17.2, 1.8 Hz, 1H), 5.20 (dd, J = 
10.5, 2.1 Hz, 1H), 4.06 (d, J = 5.1 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 136.97, 
134.27, 128.41, 128.21, 116.96, 99.63, 66.06. GC-MS observed: 238; calculated: 238. 
4.3.4 General preparation of PANDA disks 
The 100% pCBA disks were prepared by adding PETMP and pCBA at 1:1 ratio 
of SH:alkene, along with 4 wt % of Darocure 1173. The 90% pCBA disks were prepared 
by adding pCBA and TTT as another source of alkene (TTT is 10% of total alkene while 
maintaining an overall 1:1 ratio of alkene:SH) with PETMP, and Darocure 1173. The 
mixtures were well mixed and 25 μL of monomer formulations were aliquoted onto a 
glass slide and covered with another glass slide spaced with Teflon spacers (0.76 ± 0.02 
mm in thickness). The samples were then cured using an Omnicure S1000-1B with a 
100W mercury lamp (λmax = 365 nm, 320–500 nm filter) at an intensity of 200 mW 
cm−2 for 20 minutes. 
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4.3.5 Degradation of PANDAs in Phosphate Buffer Saline (PBS) 
The hydrolysis of PANDA disks was done using a slight modification of a 
method reported by Carter and coworkers.151 In general, the degradation study was 
performed in aqueous media (PBS) at pH 7.4 with a large excess of octanol to partition 
the aldehyde from the aqueous environment. Concentration was determined by measuring 
the absorbance of pCB released at 275 nm over 120 hours and extrapolated from a 
standard calibration curve. Experiments were done with n=5, with the mean and standard 
deviation reported. The 25 mm3 disks were placed at the bottom of 20 mL scintillation 
vials filled with 3 mL of PBS and 15 mL of octanol. Immediately, 100 μL octanol 
aliquots were taken out form the vial and measured for t=0. After the measurement, 
aliquots were placed back to the scintillation vials to maintain the same concentration 
throughout the kinetic study. Aliquots were analyzed at t = 0, 20, 24, 30, 48, 54, 72, 78, 
96, 102, 120 h. 
4.3.6 Degradation of PANDAs in HCl, H2O, and NH4OH chambers 
Humidity chambers were made via bubbling nitrogen gas into a vial containing 
either 12 M HCl, 30 wt% NH4OH, or deionized H2O. A cannula in the head space of the 
pressurized vial allowed transport into a secondary vial containing a 90% pCBA PANDA 
disk on a glass slide. 
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4.3.7 Evaluation of antibacterial activity of PANDAs 
The antimicrobial activity of PANDA disks was evaluated against several species 
of bacteria via the zone of inhibition method. The indicator microorganisms included 
E. coli ATCC 43895 (serotype O157:H7), Staphylococcus aureus RN6390, Burkholderia 
cenocepacia K56-2 (clinical isolate from Canada), and Pseudomonas aeruginosa PA-01. 
The testing was done on Mueller Hinton II agar (MHA) plates that were overlaid with 
soft agar seeded with individual bacterial strains. The soft agar contained (per liter): 10 g 
of Bacto Tryptone, 6 g of Difco agar, and 8 g of sodium chloride. To create an overlay, 
the indicator organisms were grown overnight at 37°C in Mueller Hinton II broth (MHB). 
The overnight cultures were diluted 1:5 with fresh MHB, and mixed with molten soft 
agar to achieve the density of ~108 CFU mL−1. From this mixture, 4-mL aliquots were 
overlaid onto MHA base plates and allowed to completely solidify. After solidifying of 
soft agar, 25 mm3 disks were overlaid on the plates and incubated at 37°C. The zones of 
inhibition (ZOI) were measured after 30 h and reported as the radius from the edge of the 
disk to the edge of the zone. Five replicates were carried out for each disk treatment and 
bacterial strain with the mean and standard deviation reported. 
4.3.8 Determination of Minimum Inhibitory Concentrations (MICs) 
MICs of the PANDA disks were determined using a modified broth macrodilution 
method. Briefly, overnight bacterial cultures in MHB were adjusted to ~105 CFU mL-1. 
Various disks of different sizes (5-50 mm3) containing pCB at concentrations ranging 
from 0.5 - 3 mg/mL of were added to 3 mL of bacterial solutions. The tubes then were 
incubated at 37 °C at 200 rpm for 30 hours. Bacteria suspended in MHB served as a 
positive control, while MHB without bacterial inoculum served as a negative control. The 
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inoculated tubes were assessed by measuring optical density at 600 nm where OD < 0.05 
considered negative for bacterial growth. 
4.3.9 Kill kinetics via terminal dilution assays 
To compare the rate of bacterial killing by 90% pCBA PANDA disks, the test 
organisms were exposed to disks and change of viable bacteria was determined by a 
modified terminal dilution method. The bacterial cultures were prepared and adjusted to 
~105 CFU mL-1 as described above. The adjusted bacterial cultures (3 mL) were mixed 
with (2 x 25 mm3) 90% pCBA PANDA disks. The inoculated tubes were incubated at 
37°C with shaking (200 rpm) and bacterial populations were determined immediately 
after the addition of disks (0 h), and at 2, 4, 8, 12, 24, and 30 hours of exposure. At each 
time point, six 100 µL aliquots of the bacterial suspensions exposed to PANDAs were 
transferred into 96-well microplates prefilled with 200 µL of MHB and serially diluted. 
The inoculated microplates were incubated for 48 h at appropriate growth temperature, 
after which the turbidity was measured with a BioTek Synergy 2 microplate reader. An 
optical density at 600 nm of  0.05 was considered positive for bacterial growth. 
Populations of viable bacteria were calculated from the final dilution (terminal dilution, 
or TD), in which bacterial growth was observed using equation 1:  
CFU
mL
=
10×3TD
1mL
 (1) 
Where TD is the terminal dilution factor obtained from microplate readings. The 
calculated CFU/mL was taken as the average of the 6 replicates and the experiment was 
repeated 3 times for each bacteria. 
4.3.10 Evaluation of antifungal activity of PANDA disks 
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The antifungal activity of 90% pCBA PANDA disks was tested against several 
species of fungus using zone of inhibition method. The indicator microorganisms 
included Candida albicans and Trichoderma harzianum. Fungus cultures were adjusted to 
OD600 0.1 for C. albicans and 10
5 ppg/mL for T. harzianum. Mueller Hinton II agar 
(MHA) plates have been spread with 100 L of fungus culture and 25 mm3 disks were 
placed on the plates.  Zone of inhibition was measured after 72 hours of incubation at 
30°C. 
4.3.11 Resistance Development Study 
This study was done using a slight modification of a method reported by Haldar and 
coworkers.153 MIC values for 90% pCBA PANDA disks were determined for P. 
aeruginosa PAO-1 as described above. For the subsequent MIC determination, bacteria 
solutions were made by using bacteria from sub-MIC concentrations of the disks (at 
MIC/2). The bacteria solution was readjusted to ~105 via OD600 readings. Into 3 separate 
vials, 3 mL of adjusted bacteria solution was added along with disks of various sizes. 
After another 24 h incubation period, bacteria solutions again were made by using 
bacteria from sub-MIC concentrations of the disks (at MIC/2). The resistance 
development study was repeated twice, each with 20 total passages. The fold increase of 
MIC was reported.  
4.3.12 MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
cytotoxicity assay 
The anti-proliferative activities of pCB and 90% pCBA PANDA degradation 
products in 3% DMSO solution were determined following a standard literature 
procedure.154 Briefly, 48 hours prior to treatment, KB cells (100,000 cells/mL, 100 μL) 
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were seeded in a 96 well plate (Corning Inc.). Cells were treated with 50 μL of pCB and 
50 μL of PANDA byproducts (media from 7 days incubation at pH 7.4). KB cells treated 
with 3% DMSO solution served as control. Cell proliferation was determined via a 
standard MTT assay (Vybrant MTT Cell Proliferation Assay Kit; Invitrogen). Cells were 
incubated for 30 h before adding 10 µL of a 12 mM MTT reagent to each well. The cells 
were further incubated for an additional 4 h, followed by removal of the media and 
addition of 50 μL of DMSO.  The absorbance was then determined utilizing a Biotek 
Synergy2 MultiMode Microplate Reader, experiment was performed in quadruplicate. 
4.4 Results and Discussion 
Initially, we synthesized an acyclic diallyl p-chlorobenzaldehyde acetal (pCBA) 
derived from pCB.  For proof-of-concept, pCB was selected from several possible 
benzaldehyde derivatives with known antimicrobial activity.155-156 Benzylic aldehyde 
derivatives are known to exert antimicrobial activity through a variety of mechanisms, 
specifically, inhibition of H+-ATPase-mediated proton pumping activity, Schiff 
base/thiazolidine formation with proteins/peptides, and membrane disruption.157-158 We 
synthesized pCBA in acceptable yields via acid-catalyzed condensation of pCB with allyl 
alcohol (1H/13C NMR Figure B.1-B.2). The antimicrobial activity of pCBA and pCB were 
evaluated via a zone of inhibition (ZOI) assay with clinically isolated strains of E. coli 
ATCC 43895 [serotype O157:H7], S. aureus RN6390, B. cenocepacia K56-2, and P. 
aeruginosa PAO1 (Figure B.3).  At the highest tested concentration (10 mg mL-1), pCBA 
exhibited no apparent antimicrobial activity.  In contrast, pCB showed significant 
inhibition at 0.5 mg mL-1 – results that indicate the acyclic acetal functions as a pro-
antimicrobial compound with antimicrobial efficacy only upon hydrolysis to the aldehyde. 
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UV-curable PANDA resins were then formulated with a photoinitiator, 
pentaerythritol tetramercaptopropionate (PETMP), and varied concentrations of pCBA 
relative to non-degradable 1,3,5-triallyl-1,3,5-triazine-2,4,6-trione (TTT) with 1:1 
alkene:thiol mole stoichiometry (Figure 4.1). Following exploratory experiments, we 
focused primarily on PANDAs synthesized from a 90:10 pCBA:TTT monomer feed as 
proof-of-principle.  This composition results in PANDA materials comprised of ~45 wt.% 
pCBA.  PANDAs were photopolymerized in the absence of solvent under a medium-
pressure UV light (200 mW cm-2).  Polymerization kinetics, investigated using real-time 
FTIR, were rapid with near quantitative conversions (>95%) observed for both thiol and 
alkene functional groups within 5 min (Figure 4.2a). The resulting PANDAs are 
transparent, low modulus thermosets with a glass transition temperature (Tg) at 0.5 °C 
(Figure 4.2b).  Although not presented in detail here, the concentration of TTT can be used 
to facilely tune the physical properties of the network (i.e., Tg, flexibility, degradation, etc.). 
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Figure 4.2 Cure kinetics, thermomechanical properties, release kinetics and degradation 
behavior of PANDAs. (a) Conversion kinetics for 90% pCBA resins cured at 200 mW 
cm-2 UV light. (b) Representative thermomechanical plot of the 90% pCBA PANDA. (c) 
Correlation between pCB released and incubation time at pH 6.0 and pH 7.4. (d) Time-
lapse macroscopic images of degradation of 90% pCBA disks submerged in PBS (pH 
7.4) and (e) placed within a 90% humidity chamber under N2 at 25 °C. (Image contrast 
enhanced for visibility). Error bars indicate the SD (n=5). 
PANDA degradation and subsequent release of pCB were investigated at pH 7.4 
and 6.0 by submerging sample disks (25 mm3) in phosphate buffer solution (PBS) 
containing octanol to partition the aldehyde. Aliquots from the octanol phase were analyzed 
via UV-vis spectroscopy to determine the concentration of pCB released over time. Figure 
4.2c shows the pCB release profile at pH 7.4 and 6.0. At physiological pH, a 20 h lag time 
was observed before pCB was slowly released from the polymer network, with 14% (1.07 
mg mL-1) and 53% (4.19 mg mL-1) pCB release observed at 24 h and 48 h, respectively. 
 60 
Similar trends were observed at pH 6 with faster release kinetics, as expected, given the 
rate of acetal hydrolysis is proportional to the H3O
+ concentration.159 After 120 h, 72% and 
80% pCB release was observed for pH 7.4 and pH 6.0, respectively. The photo series in 
Figure 4.2d shows the sample disks immersed in PBS buffer solution (pH 7.4) as a function 
of time. Shortly after immersion, the samples change from transparent to opaque white, but 
retain their shape with receding dimensions over time. The observed release and 
degradation behavior are consistent with a surface erosion process (typical of polyacetals), 
and may be expected given that these materials are relatively hydrophobic (static water 
contact angle ≈ 90°).160-161 The degradation behavior of these materials becomes 
exceedingly more interesting when exposed to water vapor (rather than bulk immersion). 
Figure 4.2e shows a photo series of PANDA disks subjected to a gentle flow of 90% 
humidity within a scintillation vial (using N2 as a carrier for water vapor to avoid 
acidification from CO2). Within 2 h, the PANDA disk hydrolyzed to a point where viscous 
flow of the sample was observed. At 4 h, the degradation byproducts are shown flowing 
down the supporting substrate.  The rapid progression from an infinite polymer network to 
viscous flow of low molecular weight degradation products is a consequence of the thiol-
ene step polyaddition mechanism – a process that ensures most crosslink junctions contain 
a degradable linkage and precludes the formation of high MW linear degradation products 
found in chain growth networks.162-163  Notably, these observations point to a rapid bulk 
degradation process and suggest a vast difference in water vapor permeability (under high 
humidity) and liquid water permeability (under immersion) that may be exploited in the 
synthetic design of humidity-triggered degradable materials.  The increased permeability 
towards water vapor is a phenomenon commonly observed in crosslinked 
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poly(dimethylsiloxane) microfluidic chips which gradually lose water due to 
evaporation.164  Furthermore, qualitative retarded degradation (Figure B.4). Experiments 
are underway to quantify the degradation behavior under vapor conditions. 
 
Figure 4.3 Antimicrobial activity and cytocompatibility assays. Error bars indicate the SD 
(n=5). (a) Correlation between zone of inhibition and % pCBA in disk after 24 h 
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incubation. (b) Kill kinetics of four bacteria in the presence of 90% pCBA PANDA via 
terminal dilution assay. (c) Bacterial resistance study of the 90% pCBA PANDA and 
tetracycline against P. aeruginosa. (d) Zone of inhibition diffusion assay of 0% and 90% 
pCBA PANDAs against C. albicans and T. harzianum. (e) Split plate diffusion assay of 
90% pCBA PANDA disks against C. albicans after 30 days. (f) Cell viability assay for 
control (DMSO), pCB, and degraded 90% pCBA PANDA. 
 
The synthetic design of PANDAs is motivated by the potential use of these 
materials in antimicrobial/ antifungal applications. The antimicrobial activity of PANDAs 
was initially evaluated via a ZOI assay with clinically isolated strains of E. coli ATCC 
43895 [serotype O157:H7], S. aureus RN6390, B. cenocepacia K56-2, and P. aeruginosa 
PAO1. As shown in Figure 4.3a, PANDAs containing 0% pCBA showed no ZOI, as 
expected, and serve as a control for the assay. PANDAs containing >60% pCBA exhibited 
ZOIs, with larger ZOIs observed for all bacteria with increasing concentration of pCBA 
(relative to TTT) in the polymer network. The antimicrobial efficacy of the 90% pCBA 
PANDA material was further investigated using a terminal dilution assay to quantify kill 
kinetics. Two 25 mm3 90% pCBA PANDA disks (3.6 mg mL-1 pCBA released within 24 
h) exhibited more than a 5 log reduction in bacteria count in < 12 h against E. coli, S. 
aureus, and other pathogens (Figure 4.3b), which translates into kill efficiencies of 
>99.999%. In interest of developing strategies and materials to mitigate the development 
of antimicrobial resistance, we evaluated the potential emergence of bacterial resistance of 
P. aeruginosa against pCBA-based PANDAs using a serial passage mutagenesis assay.  
For comparison, the same assay was performed using tetracycline. Figure 4.3c shows the 
inability of P. aeruginosa to develop resistance toward pCB released from PANDA disks 
after 20 serial passages as indicated by the absence of an increase in the MIC (25 mm3 disk 
≈ 1.3 mg mL-1 pCB released within 24 h). We note that the concentration of pCB released 
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from the disk after 24 h is comparable to the small molecule MIC at 1.25 mg mL-1.  In 
contrast, the MIC value for tetracycline increased after only two passages, with a 10-fold 
increase in MIC after 20 passages. The results suggest that P. aeruginosa has less 
propensity to develop resistance against the pCB released from pCBA-based PANDAs, 
which highlights the potential of PANDAs for use as part of a broader strategy to slow or 
mitigate the development of antimicrobial resistance. 
To further probe the broad-spectrum activity of pCBA PANDAs, we performed 
zone of inhibition experiments against two opportunistic pathogenic fungi (C. albicans and 
T. harzianum).165-166 Placement of a 25 mm3 90% pCBA PANDA disk resulted in complete 
inhibition of both fungi whereas the same size disks containing 0% pCBA exhibited no 
measurable antimicrobial activity (Figure 4.3d). Borrowing from the known inhibitory 
activity of volatile EOs, we exploited the inherent volatility of pCB to inhibit  C. albicans 
– a  pathogenic fungus responsible for up to 65% of all candidiasis cases in humans – via 
a split plate inhibition volatility assay.166 As shown in Figure 4.3e, 25 mm3 90% pCBA 
PANDA disks were placed on one side of a 9 cm split Petri dish with C. albicans plated on 
agar on the opposite side. The dish was sealed and incubated for 30 days. In the absence of 
PANDA disks (control), zero inhibition was observed. Partial inhibition was observed with 
one disk, while the growth of C. albicans was completely inhibited by two disks for up to 
30 days. These experiments exploit the humidity-triggered degradation and volatility of 
pCB for non-contact control of fungus.  Finally, KB cells (a type of HeLa cells), derived 
from a glandular cancer of the cervix were used as a model cell line for cytotoxicity.167 
Incubation of the KB cells with a degraded 90% pCBA disk (e.g. media containing 
PANDA degradation products after 7 days at pH 7.4, equivalent to 2.5 mg mL-1 pCB) and 
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small molecule pCB at the same concentration showed no significant toxicity (>90% 
viability) to KB cells (Figure 4.3f). 
In summary, we have demonstrated the proof-of-principle for pro-antimicrobial 
networks via degradable acetals.  PANDAs undergo degradation under mild conditions to 
release pCB – a small molecule active that serves as a potent antimicrobial agent against a 
broad spectrum of microbes. The humidity triggered degradation and volatile release of 
pCB was exploited to inhibit the growth of C. albicans without the need for direct contact.  
Importantly, the broad spectrum antimicrobial efficacy was achieved with minimal 
cytotoxicity towards KB HeLa cells. Solvent-free, room temperature photopolymerization 
provides a rapid, one-pot approach to crosslinked polyactives with excellent potential for 
advanced processing techniques, including 3D printing.  The PANDA approach presented 
here is readily applicable to other bioactive aldehydes pointing to the potential use of these 
materials within pharmaceutical, biomedical, and agricultural industries. 
4.5 Conclusions 
We have reported that PANDAs, building upon linear “polyactives”, represent a new 
paradigm for sequestration and triggered release of volatile, bioactive aldehydes.  As proof-
of-concept, we showed that PANDAs derived from diallyl p-chlorobenzaldehyde acetal 
and pentaerythritol tetramercaptopropionate degrade and release p-chlorobenzaldehyde 
(pCB) as an antibacterial and antifungal agent under mild conditions (pH 7.4/high 
humidity).  Notably, the thiol-ene step polyaddition process ensured that most crosslink 
junctions contain a degradable acetal linkage enabling rapid progression from an infinite 
polymer network to low molecular weight degradation products.  We showed that 
PANDAs enable facile access to materials sequestering up to 50 wt% pCB with tunable 
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release profiles, potent antimicrobial activity against Gram positive and Gram negative 
bacteria without triggering antimicrobial resistance, and minimal cytotoxicity.  We also 
demonstrated the utility of PANDA materials by exploiting humidity-triggered degradation 
and volatile release of pCB from the polymer network for vapor-phase inhibition of 
Candida albicans – where a 50 µL PANDA disk provided 30 days of inhibition. To our 
knowledge, this represents a first example of the pro-antimicrobial approach manifested in the form 
of crosslinked polymer networks exhibiting broad spectrum antimicrobial activity.  Significantly, 
the PANDA approach is readily applicable to sequestration and release of other bioactive 
aldehydes and is translatable to various material geometries (e.g., particles, thin films, 
printable scaffolds) pointing to potential use of these materials within pharmaceutical, 
biomedical, and agricultural applications.
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CHAPTER V – A BIO-BASED PRO-ANTIMICROBIAL POLYMER NETWORK VIA 
DEGRADABLE ACETAL LINKAGES 
5.1 Abstract 
The synthesis of a fully degradable, bio-based, sustained release, pro-
antimicrobial polymer network comprised of degradable acetals (PANDA) is reported. 
The active antimicrobial agent – p-anisaldehyde (pA) (an extract from star anise) – was 
converted into a UV curable acetal containing pro-antimicrobial monomer and 
subsequently photopolymerized into a homogenous thiol-ene network. Under neutral to 
acidic conditions (pH < 8), the PANDAs undergo surface erosion and exhibit sustained 
release of pA over 38 days. The release of pA from PANDAs was shown to be effective 
against both bacterial and fungal pathogens. From a combination of confocal microscopy 
and transmission electron microscopy, we observed that the released pA disrupts the cell 
membrane. Additionally, we demonstrated that PANDAs have minimal cytotoxicity 
towards both epithelial cells and macrophages. Although a model platform, these results 
point to promising pathways for the design of fully degradable sustained-release 
antimicrobial systems with potential applications in agriculture, pharmaceuticals, 
cosmetics, household/personal care, and food industries. 
5.2 Introduction 
With the increasing prevalence of antimicrobial resistance (AMR), opportunistic 
pathogens pose a significant global crisis. Compounding the issue, over 23.5 million 
immunocompromised patients (i.e. patients with rheumatoid arthritis, HIV, organ 
transplants, etc.) are prescribed immunosuppressants, making them more prone to both 
fungal and bacterial infections 168. For instance, the fungus Histoplasma capsulatum 
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aggressively infects immunocompromised patients with over 500,000 cases annually in 
the United States, 300,000 of which are HIV-related infections resulting in 10,000 deaths 
per year 169. Additionally, exposure to other common pathogens such as Pseudomonas 
aeruginosa, Escherichia coli, Salmonella Typhi, and Staphylococcus aureus can escalate 
into life threating infections resulting in sepsis and death 170-171. To combat AMR, new 
antimicrobial strategies with low propensity to trigger resistance have been developed 
including quorum sensing inhibitors 172, synergistic pairing to induce sensitivity 173-174, 
antibiotic adjuvants 175, antibiotic cycling 176, and multimodal antibiotics 177-178. Of the 
aforementioned methods, essential oils (EOs) – a unique class of naturally occurring, 
plant-derived extracts – hold promise in eradicating resistant microbial populations via 
the multimodal approach. EOs exhibit broad spectrum antimicrobial activity by 
interfering with membrane integrity, ATP synthesis, protein stability, and quorum 
sensing pathways 3, 16.  Despite positive results, the use of EOs is still restricted due to 
their limited water solubility, high volatility, and chemical instability 17. Many 
approaches have been reported to sequester EO derivatives within polymeric materials; 
however, these strategies often utilize slow or non-degradable linkages which slowly 
release or permanently entrap EOs. 
Poly(actives), or polymeric pro-drugs that rely on degradable linkages for the 
release of therapeutic agents, can improve chemical stability, enable tunable release 
profiles, and reduce volatility 24. Multiple linear poly(actives) have been reported 
including poly(esters) 179-180, poly(anhydride-esters) 138, 181-187, poly(anhydride-amides) 
188, poly(carbonate-amides) 189, poly(carbonate esters) 190, poly(ketals) 191, and 
poly(oxalate-acetals) 25. While linear poly(actives) successfully entrap drugs and allow 
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for tunable release profiles, crosslinked poly(actives) represent a relatively unexplored 
class of degradable drug-releasing materials where opportunities for greater control over 
degradation profiles, thermomechanical properties, and sample geometry (particles, thin 
films, or coatings) are available. Recently, crosslinked poly(actives) including 
poly(esters) 144, 192-193, poly(-amino esters) 194, and poly(acetals) 68 have utilized 
degradation rates, crosslink density, and hydropathy as mechanisms to control the release 
of actives. Of the degradable linkages available, both acetals and ketals have gained 
recent attention because of their charge-neutral and potentially nontoxic byproducts 
(alcohols and ketones/aldehydes) upon cleavage 195.  
We have recently demonstrated the sequestration of p-chlorobenzaldehyde within 
a pro-antimicrobial network via degradable acetals (PANDA) 68. While p-
chlorobenzaldehyde is a relatively potent antimicrobial drug, we wanted to shift focus 
away from oil derived compounds and towards bio-based aldehydes found in nature to 
offer a fully degradable antimicrobial system based on essential oils. In this work, we 
turned towards p-anisaldehyde (pA), an extract from star anise (Pimpinella anisum) 
seeds, to fabricate a new class of antimicrobial PANDAs. We demonstrate that 
incorporation and subsequent release of pA from a PANDA exhibits potent antimicrobial 
activity against a variety of clinically relevant pathogens with minimal cytotoxicity. 
5.3 Experimental 
5.3.1 Materials 
The chemicals p-anisaldehyde (pA), trimethylol propane diallyl ether, 2-hydroxy-
2-methylpropiophenone (Darocur 1173), trimethylsilyl trifluoromethanesulfonate 
(TMSOTf), dichloromethane (DCM), allyloxytrimethylsilane, pyridine, sodium 
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bicarbonate, diethyl ether, magnesium sulfate (MgSO4), dextrose, 2,3,5,6-
tetrachloronitrobenzene, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), hexane, 0.5 M Tris-HCl in H2O, acetonitrile-d3, Aqua Dead Cell Stain™, 
LIVE/DEAD BacLight Bacterial Viability Kit staining kit, BacLight RedoxSensor CTC 
Vitality Kit and ethyl acetate were acquired from Thermo Fisher Scientific. 
Pentaerythritol tetra(3-mercaptopropionate) (PETMP) was provided by Bruno Bock. 
Difco Agar, yeast extract, Bacto Tryptone, Mueller Hinton broth and agar, were from 
Becton, Dickinson and Company. Ham's F-12 and trypsin-EDTA were obtained from 
GIBCO. Hemin chloride (type II), protoporphyrin IX, histidine (free base), proline, 37% 
formaldehyde in H2O, dimethyl sulfoxide (DMSO), fluconazole, fetal bovine serum 
(FBS), Dulbecco's Modified Eagle's Medium (DMEM) and N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid (HEPES) was purchased from Sigma Aldrich. All the materials 
were obtained at the highest purity available and used without further purification unless 
otherwise specified. 
5.3.2 Characterization Methods. 
A Bruker Ascend 600 MHz (TopSpin 3.5) spectrometer was used to record 1H/13C 
NMR spectra with either chloroform-d or acetonitrile-d3. High resolution mass 
spectroscopy (HRMS) was performed with positive electrospray ionization on a Bruker 
12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source. Dynamic mechanical 
analysis (DMA) was performed using a TA Instruments Q800 dynamic mechanical 
analyzer in tension mode equipped with a gas cooling accessory. Samples were clamped, 
evaluated at a strain of 1 %, and heated from -80 °C to 80 °C at a ramp rate of 3 °C min-1. 
Kinetic data was obtained using real-time FTIR (RT-FTIR) spectroscopy by determining 
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the conversions of the thiol and ene functional groups. The RT-FTIR studies were 
conducted using a Nicolet 8700 FTIR spectrometer with a KBr beam splitter and a 
MCT/A detector with a 320–500 nm filtered ultraviolet light source. Each sample was 
exposed to a UV light with an intensity of 400 mW cm-2. Series scans were recorded, 
where spectra were taken approximately 2 scan s-1 with a resolution of 4 cm-1. Thiol 
conversion was monitored via integration of the SH peak between 2500-2620 cm-1 while 
the conversion of the alkene was monitored between 3050-3125 cm-1. Optical density 
(OD) and fluorescence readings were performed in a BioTek Synergy 2 programmable 
microplate reader (BioTek Instruments). 
5.3.3 Synthesis of p-anisaldehyde diallylacetal (pAA) 
The synthesis of pAA was done using a slightly modified procedure from Noyori 
and coworkers 196. To a flame dried 250 mL round bottom equipped with a stirbar, 
TMSOTf (200 µL, 1.1 mmol) was added along with 30 mL dry DCM under nitrogen at -
84 °C. While maintaining the same temperature, a mixture of allyloxytrimethylsilane (37 
mL, 208 mmol) and pA (12 g, 88 mmol) in 25 mL of dry DCM was added dropwise into 
the round bottom. The reaction turned yellow and stirred for 3 h. After, the reaction was 
warmed to -30 °C and stirred for 1 h (reaction turned red). The deep red mixture was then 
quenched with the addition of pyridine (15 mL, 74.5 mmol) and poured into 100 mL of 
saturated sodium bicarbonate prior to extraction with (3 x 100 mL) of diethyl ether. The 
organic layer was dried over anhydrous MgSO4, then the excess solvent was removed 
under reduced pressure. The yellow oil was then purified via column chromatography 
using a mixture of hexane: ethyl acetate (9:1) and yielded a clear oil (13.6 g, 65.9 % 
yield). 1H NMR (CDCl3) δ 7.45 (dd), 6.93 (dd), 5.97 (m), 5.62 (s), 5.35 (dd), 5.17 (dd), 
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4.07 (d), 3.82  (s). 13C NMR (CDCl3) δ 159.66, 134.16, 130.68, 127.97, 116.67, 113.52, 
100.29, 66.00, and 55.22. HRMS (ESI+) m/z calculated for C14H18O3 [M+Na]
+ 
257.114816; Found 257.114817. 
5.3.4 General preparation of PANDA disks 
The PANDA disks were prepared by adding PETMP and pAA at 1:1 ratio of SH:alkene, 
along with 4 wt.% of Darocur 1173. The mixtures were well mixed and 25 μL of the 
monomer formulations were aliquoted onto a glass slide and covered with another glass 
slide spaced with Teflon spacers (0.76 ± 0.02 mm in thickness). The samples were then 
cured using an Omnicure S1000-1B with a 100W mercury lamp (λmax = 365 nm, 320–
500 nm filter) at an intensity of 400 mW cm−2 for 40 seconds. Control disks were 
prepared following the same procedure by using PETMP and trimethylol propane diallyl 
ether at 1:1 ratio of SH to alkene with addition of 4 wt.% of Darocur 1173.. 
5.3.5 Degradation of PANDAs 
The hydrolysis of PANDA disks was analyzed via 1H NMR under a pH 7.4 Tris-
HCl buffered water:acetonitrile-d3 solution. First 2,3,5,6-tetrachloronitrobenzene (internal 
standard) was weighed into a vial along with 500 µL of acetonitrile-d3. Then 125 µL of 
100 mM Tris-HCl in deionized water was added and mixed. A 5 mm3 disk and 500 µL of 
the acetonitrile:buffer solution was added to an NMR tube and sealed. Three replicates 
were prepared for each data point (with mean and standard deviation reported) and NMR 
spectra were taken over 38 days. To calculate the concentration released of different sized 
PANDA disks (5-100 mm3), the grams of pA released (at 24 and 48 h from a 5 mm3 disk) 
were multiplied by a factor to equal the desired PANDA disk size (e.g. x10 for a 50 mm3 
disk) and divided by the total volume the disk was placed into. Since the thickness of the 
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PANDA disks does not change, this assumption is valid, however the degradation profile 
in the presence of microbes may not be the same as pH 7.4 PBS, yet remains our best 
estimate. 
5.3.6 Evaluation of antibacterial activity of PANDAs 
5.3.6.1 Zone of inhibition (ZOI) assay 
The antimicrobial activity of PANDA disks was tested against several species of 
bacteria via the zone of inhibition method. The indicator microorganisms included 
Escherichia coli ATCC 43895 (serotype O157:H7), Staphylococcus aureus RN6390, 
Salmonella enterica serovar Typhi ATCC 6539 (S. Typhi), and Pseudomonas aeruginosa 
PAO1. The testing was done on Mueller Hinton II agar (MHA) plates that have been 
overlaid with soft agar seeded with individual bacterial strains. The soft agar contained 
(per liter): 10 g of Bacto Tryptone, 6 g of Difco agar, and 8 g of sodium chloride. To 
create an overlay, the indicator organisms were grown overnight at 37 °C in Mueller 
Hinton II broth (MHB). The overnight cultures were diluted 1:5 with fresh MHB, and 
mixed with molten soft agar to achieve a ~108 CFU mL−1 density. From this mixture, 4 
mL aliquots were overlaid onto MHA base plates and allowed to completely solidify. 
After solidification of the soft agar, 50 mm3 disks were overlaid on the plates and 
incubated at 37 °C. The zones of inhibition (ZOI) were measured after 24 h and reported 
as the distance from the edge of the disk to the edge of the zone. Three replicates were 
carried out for each disk/bacterial strain. with the mean and standard deviation reported 
(experiment was repeated twice). 
5.3.6.2 Minimum inhibitory assay 
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Minimum size of PANDA disks required to inhibit bacterial growth were 
determined using a modified broth macrodilution method. Briefly, overnight bacterial 
cultures in MHB were adjusted to ~105 CFU mL-1. PANDA disks of different sizes (5-
100 mm3) were added to 4 mL of bacterial solutions. The tubes were then incubated at 37 
°C and shaken at 200 rpm for 24 h. Bacteria suspended in MHB served as a positive 
control, while MHB without bacterial inoculum served as a negative control. The 
inoculated tubes were assessed by measuring optical density at 600 nm after 24 h where 
OD < 0.05 considered negative for bacterial growth. Three replicates were carried out for 
each disk size and bacterial strain. with the mean and standard deviation reported 
(experiment repeated twice). 
5.3.6.3 Kill kinetics via track dilution assays 
To compare the rate of bacterial killing by PANDA disks, the test organisms were 
exposed to 100 mm3 PANDA disk and the number of viable bacteria was determined by a 
modified kinetic track dilution method 197. Individual disks were submerged in 4 mL 
aliquots of bacterial cultures adjusted to ~105 CFU mL-1 as described above and 
incubated at 37 °C with shaking (200 rpm). Bacterial populations were determined 
immediately after the addition of disks (0 h), and at 4, 8, 16, 24, 30, and 48 h of exposure. 
For the track-dilution technique, Falcon 15-mm square plates with 13-mm grids (Becton 
Dickinson Labware) were used. At each time point, six 20 µL aliquots of the bacterial 
suspensions exposed to PANDAs were transferred into 96-well microplates prefilled with 
200 µL of MHB and serially diluted 1 to 10 to reach a final dilution of 10-8. From 
inoculated samples, 10 µL were spotted on the agar surface along one side of the square 
plate using a multichannel micropipette. The plate was tipped onto its side (at a 45°–90° 
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angle), to allow inoculum to migrate in parallel tracks across the agar and to dry for 1 
min. The plate was then inverted and incubated for 24 h at 37 °C prior to colony 
counting.  Bacteria suspended in 4 mL MHB served as a positive control, while MHB 
without bacterial inoculum served as a negative control. Three replicates were carried out 
for each time point and bacterial strain with the mean and standard deviation reported 
(experiment repeated twice). 
5.3.6.4 Determination of respiratory activity 
A BacLight RedoxSensor CTC Vitality Kit was used to evaluate respiratory 
activity of bacteria (adjusted to ~105 CFU mL-1) exposed to either PANDA disks or 
control disks (100 mm3) after a 24 h incubation at 37°C at 200 rpm. According to the 
manufacturer’s protocol, 5-cyano-2,3-ditolyl tetrazolium chloride (CTC) (15 mg) was 
dissolved in 1 mL of sterile deionized water. Next, 180 µL of each sample was mixed 
with 20 µL of the CTC solution in a Corning™ 96-well solid black microplate and 
incubated at 37 °C for 30 min prior to reading with a BioTek reader equipped with a 
monochromator at 450 nm excitation and 630 nm emission. 
5.3.6.5 Assessment of cell membrane integrity 
Bacterial cell membrane integrity was evaluated using a LIVE/DEAD BacLight 
Bacterial Viability Kit. A 4 mL of ~105 CFU mL-1 P. aeruginosa was prepared and 
exposed to a 100 mm3 PANDA disk, prior to incubation at 37 °C with constant shaking 
(200 rpm). From each inoculated sample, 100 µL aliquots of the bacteria from the 
PANDA treatment were transferred into a Corning™ 96-well solid black microplate, and 
mixed with 100 µL of the LIVE/ DEAD BacLight staining reagent. The samples were 
taken at 0 and 30 h and incubated in the dark for 15 min. The fluorescence was measured 
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using a 485/20 nm excitation filter (for both SYTO9 and propidium iodide) and two 
separate emission filters:  528/20 nm (SYTO9 emission wavelength) and a 620/40 nm (PI 
emission wavelength). For confocal imaging, 5 µL of the stained samples were cast onto 
separate microscope slides. Each sample was assayed in triplicate, and the experiment 
was repeated twice. From the inoculated sample, transmission electron micrographs were 
taken with a Zeiss 900 electron microscope operating at 50 kV and outfitted with a Model 
785 Erlangshen ES1000 WCCD camera (Gatan). Samples were applied to 200 mesh 
copper grids (3.05 mm, 200 lines per inch square mesh, Electron Microscopy Sciences) 
coated with Formvar (5% polyvinyl formal resin). 
5.3.7 Determination of antifungal activity 
5.3.7.1 Zone of inhibition assay 
The wild-type Histoplasma capsulatum G217B (ATCC 26032) strain was used in 
this study. Liquid H. capsulatum yeast cultures were grown to mid-log (OD600 ~1.4-1.9) 
in Histoplasma macrophage medium (HMM) 198 and enumerated using a hemocytometer 
(Incyto C-Chip). Once quantified, 1.0 x 107 cells were spread in triplicate onto pre-
warmed solid HMM plates and allowed to dry for 1 h before PANDA disks (50 mm3) 
were overlaid in the center of each plate. After 4 days of incubation at 37 °C in 5% CO2 / 
95% room air, images were captured using a DinoLite microscope camera and zones of 
inhibition were measured using the DinoLite software. For a negative control, a control 
disk was added, whereas, the positive control contained 4 mg fluconazole. Three 
biological replicates were used to calculate mean and standard deviation (experiment 
repeated twice). 
5.3.7.2 Determination of minimum inhibitory concentration (MIC) 
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Four-day-old H. capsulatum yeast cultures were diluted 1:5 and grown overnight 
at 37 °C in 5% CO2 / 95% room air with shaking (200 rpm). Cells were then diluted with 
pre-aerated, pre-warmed HMM to a final OD600 of 0.1. Various sizes of PANDA disks 
(0-45 mm3) were added to 50 mL aliquots of the diluted yeasts as described above. The 
cultures were then incubated for a total of 7 days. Every 24 h, 1 mL aliquots of each 
culture were transferred to disposable plastic cuvettes and OD600 was measured using a 
BioTek reader. After 7 days, a growth curve of OD600 vs. time was generated to 
determine MICs. The experiment was repeated twice. 
5.3.7.3 Fungal viability 
For LIVE/DEAD staining of H. capsulatum yeast-phase cells, 1 mL aliquots of a 
mid-log phase culture of H. capsulatum challenged with either 45 mm3 control or 
PANDA disks was centrifuged at 1000 × g for 5 min, washed once with PBS, and re-
suspended in PBS.  Next, cells were enumerated via hemocytometry and diluted to 1 x 
106 cells per mL. At this point Aqua Dead Cell Stain™ was added to the cell suspension 
in a final dilution of 1:1000 and incubated for 30 min at room temperature in the dark.  
Once labelled, the cells were washed with PBS and fixed with 37% formaldehyde for 15 
min at room temperature.  Flow cytometry was performed on a BD Accuri C6 Flow 
Cytometer using an excitation wavelength of 405 nm with emission capture at ~525 nm.  
A gate was then applied and viability assessed by analyzing the shift in fluorescent 
intensity.  To qualitatively assess fungal viability, the same labelled cells were analyzed 
on a Zeiss LSM 510 Meta confocal microscope at 40x magnification using both 
differential interference contrast and 405 nm laser excitation.    
5.3.7.4 Direct contact mammalian cell viability 
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To assess the effects of the PANDAs directly on host cells, a direct contact assay 
based on ISO 10993-5 with MTT was used to quantify viability of RAW 264.7 murine 
macrophages and VERO epithelial cells (isolated from kidney) after the addition of either 
control (1.5 mm3) or PANDA disks (0.5, 1.0, and 1.5 mm3) 199. Cells with no additional 
supplementations were used as a control. Six replicates were measured to calculate 
percent survival and standard deviation. The MTT assay was carried out per the 
manufacturer’s protocol (Thermo Fisher) with modifications to adapt the assay from the 
standard 96-well plate to a 24-well cell culture plate. Both RAW 264.7 and VERO cell 
lines were maintained in 20 mL DMEM supplemented with 10% FBS, 50 µg mL-1 
ampicillin, 4.5 mg mL-1 glucose, 584 µg mL-1 L-glutamine, and 100 µg mL-1 
streptomycin in T-150 culture flasks (Sigma). Cells were incubated at 37 °C in 5% CO2. 
Briefly, cells were grown to confluence and detached from the culture flask with trypsin-
EDTA and centrifuged briefly at 200 × g for 5 min. They were then re-suspended in 1 mL 
DMEM and enumerated using a hemocytometer. The cells were diluted to 5.0 x 104 cells 
mL-1 and 1 mL aliquots were added to each well of a 24-well cell culture plate (Sigma). 
Once the culture reached subconfluency (~80% confluency) in the 24-well plate, 1.5 mm3 
disks were overlayed on the cells and allowed to incubate for 24 h at 37 °C in 5% CO2. 
After the incubation, all media were removed from the wells and replaced with 500 µL of 
Dulbecco’s phosphate-buffered saline (DPBS), pH 7.5. 50 µL of 12 mM MTT was then 
added to each well and incubated at 37 °C for 2 h. After labelling the cultures with MTT, 
all but 250 µL of DPBS/MTT mixture was removed from the wells. To solubilize the 
MTT dye, 500 µL of DMSO was added to each well and mixed thoroughly before 
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incubating at 37°C for 10 min. Lastly, each 24-well plate was mixed and absorbance was 
read at 540 nm. Experiment was repeated twice. 
5.3.7.5 Statistical Analysis 
All measurements were made in triplicate unless otherwise stated and each 
experiment was performed on at least two separate occasions; the results are expressed as 
the average of the parallel assays with error bars representing a standard deviation from 
the mean.” 
5.4 Results and Discussion 
5.4.1 Monomer synthesis and PANDA fabrication/properties 
As shown in Scheme 5.1A, the acyclic diallyl p-anisaldehyde acetal (pAA) was synthesized 
in modest yields (66% after column) through Noyori’s acetal forming procedure by the 
reaction of allyloxytrimethylsilane with pA in the presence of TMSOTf  (1H NMR, Fig. 
5.1A) 196. To assess the pro-antimicrobial nature of pAA, 10 µL of pure pAA and pA were 
placed on plates overlayed with S. Typhi (Scheme 5.1A). After 24 h of incubation, pAA 
showed no apparent zone of inhibition indicating no antimicrobial activity. In contrast, pA 
showed a 1 cm zone of inhibition indicating that pAA functions as a pro-antimicrobial 
compound only exhibiting antimicrobial activity upon hydrolysis back to pA. 
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Scheme 5.1 Overview of monomer synthesis and PANDA fabrication. (A) Synthesis of 
pro-antimicrobial pAA from antimicrobial pA. Antimicrobial properties of pAA/pA are 
indicated by a zone of inhibition assay against S. Typhi. (B) Monomers used to 
synthesize the PANDAs via thiol-ene photopolymerization and acid mediated 
transformation of pAA to pA. (C) Schematic depiction of PANDA degradation 
mechanism. 
To fabricate PANDAs, pentaerythritol tetrakis(3-mercaptopropionate) (PETMP), 
photoinitiator and pAA were copolymerized with 1:1 alkene/thiol mole stoichiometry via 
radically mediated step-growth thiol-ene photopolymerization (Scheme 5.1B). The 
fabricated PANDAs are comprised of 47 wt.% pAA which corresponds to 27 wt.% pA 
loading. The polymerization kinetics are rapid and exhibit nearly quantitative monomer 
conversion (>95%, Fig. 5.1B) for both thiol and alkene functional groups within seconds 
under a medium pressure UV light (400 mW cm−2). The step-growth polymerization 
ensures that each crosslink junction contains a hydrolytically cleavable acetal linkage for 
the release of pA from the network (Scheme 5.1C). Additionally, the resulting PANDAs 
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possess a narrow tan  (indicative of a homogenous network), a glass transition temperature 
of -0.5 °C (Fig. 5.1C), and are optically transparent – typical of thiol-ene materials 33.  
 
Figure 5.1 Monomer structure, cure kinetics, and final network properties. (A) 1H NMR 
spectra of pAA. (B) Real-time FT-IR of SH and ene conversion during 
photopolymerization. (C) Dynamic mechanical analysis of the resulting PANDA. 
5.4.2 PANDA release kinetics 
The release kinetics of pA from the PANDAs were monitored via 1H NMR spectroscopy 
over 38 days at pH 7.4 by submerging disks in buffered solutions in acetonitrile-d3 within 
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sealed NMR tubes. An internal standard, 2,3,5,6-tetrachloronitrobenzene ( = 7.75 ppm), 
was added to the buffered solution and integrated relative to the benzylic aldehyde proton 
( = 9.85 ppm) to determine the concentration of pA over time (Fig. 5.2A). Figure 5.2B 
shows the release profile of pA from the integrated 1H NMR results. At physiological pH, 
no burst release was observed and 90% pA was released after 38 days. The release profile 
was then fit to the cylindrical Hopfenberg model 200 described as:  
𝑀𝑡
𝑀∞
= 1 − [1 −
𝑘0𝑡
𝐶0𝑎
]
2
 
where, 𝑀𝑡 is the concentration of released pA at time t, 𝑀∞ is the theoretical maximum of 
pA released, 𝑘0 is the erosion rate constant, 𝐶0 is the initial concentration of drug in the 
matrix, and a is the initial radius of the cylinder. From the Hopfenberg model, the half-life 
was determined to be 14.9 days and the fit was in good agreement with the release data as 
indicated by an r2 value of 0.989. To verify the surface erosion of the PANDAs, control 
(PETMP and trimethylolpropane diallyl ether) and PANDA disks were fabricated, 
immediately submerged in a 1N aqueous HCl solution, and imaged over time. Within 1 h, 
significant surface erosion was visually observed as noted by the degradation front 
highlighted by the green arrows in Figure 5.2C. Due to the immiscibility of the degradation 
byproducts in water, the solid disk gradually transitions to an oil-like residue within 3 h. 
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Figure 5.2 Degradation of PANDAs. (A) 1H NMR degradation kinetics of PANDA at pH 
7.4. (B) Cumulative release of pA from PANDA subjected to pH 7.4. (C) Kinetic optical 
microscopy images of a PANDA disk submerged in 1 N HCl. Green arrows indicate 
remaining PANDA disk. (D) Calculated cumulative area from 1N HCl degradation 
kinetics determined by imageJ analysis. 
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A plot of the remaining disk area at time t (At) relative to the initial area (A) was 
plotted overtime and then fit by the Hopfenberg model, where 𝑀𝑡/𝑀∞ were replaced by 
𝐴𝑡/𝐴∞ (Fig. 5.2D). In comparison to the degradation at pH 7.4, the degradation at pH 0.1 
was 380x faster (half-life = 0.04 days), indicating that PANDA degradation is acid 
sensitive. While small molecule model studies show that acetal degradation is generally 10 
times faster with each unit of pH decrease201, Liu et al. reported that crosslinked acetal 
network degradation follows small molecule degradation kinetics qualitatively195. 
Moreover, Garripelli and coworkers showed that acetal-based material degradation does 
not follow first order kinetics relative to the hydronium ion concentration202. The 
differences between network and small molecule degradation are likely attributed to 
differences in accessibility of the acid to each acetal as well as the hydropathy of the 
crosslinked network.  
5.4.3 PANDA antibacterial activity 
5.4.3.1 Bacterial inhibitory assays  
The use of pA was motivated by its potent activity exhibited in screening experiments 
against pathogenic bacteria. The antimicrobial activity of 50 mm3 PANDAs and control 
disks was initially evaluated via a ZOI assay with clinically isolated strains: S. aureus 
RN6390 and P. aeruginosa PAO1, and foodborne pathogens: E. coli ATCC 43895 
(serotype O157:H7) and S. Typhi ATCC 6539 (Fig. 5.3A). In all cases, the control disks 
showed no inherent antimicrobial activity towards any bacteria, whereas zones of 
inhibition (>1 cm) were present for the PANDA disks. The ZOI assay showed that the 
order of antimicrobial inhibition was S. Typhi > S. aureus > E. coli O157:H7 > P. 
aeruginosa. 
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Figure 5.3 Antibacterial activity of PANDAs. (A) ZOI of PANDA and control disks. 
Plotted data points represent individual measurements. (B) Minimum inhibition assay of 
different sized PANDA disks. (C) Time-dependent killing of pathogens by 100 mm3 
PANDA disks. Data are representative of 2 independent experiments ± s.d. 
To determine the PANDA disk size required to inhibit bacterial growth, a minimum 
inhibitory disk size assay was performed with exponentially grown bacteria (105 CFU mL-
1 in 4 mL media) challenged with PANDA disks (0-100 mm3). As shown in Figure 5.3b, 
an increase in disk size correlates with an increase in bacterial inhibition with a 100 mm3 
PANDA disk [910 µg mL-1 released after 24 h (determined from Fig. 5.2B)] completely 
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inhibiting the growth of all bacteria. The trend in bacterial susceptibility from the ZOI 
assay was also observed in the minimum inhibition assay with E. coli O157:H7 and P. 
aeruginosa requiring the largest PANDA disk (100 mm3), while S. Typhi and S. aureus 
were inhibited by a 50 mm3 PANDA disk [455 µg mL-1 released after 24 h (determined 
from Fig. 5.2B). These determined MICs are in good agreement with other inhibition 
studies involving pA 8.  
5.4.3.2 Determination of bacteriostatic/bactericidal activity of PANDA disks 
To examine the bactericidal activity of 100 mm3 PANDA disks, the number of viable 
bacteria was quantified via a kinetic track dilution assay at 0, 4, 8, 16, 24, 30, and 48 h 
(Fig. 5.3C). The PANDA disk (1085 µg mL-1 pA released within 48 h) exhibited 
bactericidal activity with a >4 log reduction in bacteria count (>99.99% elimination) 
against P. aeruginosa, E. coli, and S. Typhi. However, the concentration of gram-positive 
S. aureus remained constant at 105 CFU mL-1, indicating a bacteriostatic effect. Our results 
are in agreement with previous studies which have shown that the 
bactericidal/bacteriostatic activity is dependent on both EO concentration and bacterial 
species 203-204. 
5.4.3.3 Evaluation of bacterial respiratory activity and membrane integrity 
To investigate the antibacterial efficacy of PANDA disks (100 mm3), a series of 
physiological assays along with micrographs were performed. The fluorogenic probe, 5-
cyano-2,3-ditolyl tetrazolium chloride (CTC) was used to measure bacterial respiratory 
activity. Bacteria capable of respiration reduce CTC into CTC-formazan (CTF), an 
insoluble, fluorescent product that can be quantified via fluorescence readings. As shown 
in Figure 5.4A, in comparison to the control disks, bacteria treated with PANDAs showed 
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a 90-95% loss of fluorescence indicating a significant decrease in respiratory activity. 
Interestingly, with S. aureus, PANDAs had a bacteriostatic effect and the population 
remained unchanged despite the significant decrease in metabolic activity. The different 
response of bacteria to pA is not unprecedented as some antibiotics can act as both 
bactericidal or bacteriostatic agents 205. Lobritz et al. 205 attributed the differences between 
the bactericidal or bacteriostatic modes of actions to the interference with cellular 
respiration. Bactericidal antibiotics cause an acceleration in respiration and basal 
metabolism that ultimately lead to cell death. In contrast, bacteriostatic antibiotics suppress 
cellular respiration and translation thus interfering with killing. It is plausible that the 
altered responses of S. aureus and the tested gram-negative species to pA are caused by the 
different effect of pA on metabolism in these microorganisms.  We also investigated the 
effect of PANDA disks (100 mm3) on membrane integrity of P. aeruginosa stained with 
SYTO9 and propidium iodide at 0 h and 30 h by confocal imaging. Green-fluorescing 
SYTO9 can penetrate intact and damaged bacterial membranes, whereas red propidium 
iodide enters only cells with damaged cytoplasmic membranes and displaces SYTO9, 
leading to red fluorescence when both dyes are present 206. Prior to PANDA exposure (0 
h), a majority of cells fluoresce green indicating intact membranes while after 30 h, a large 
number of cells fluoresce red denoting damage of the cytoplasmic membranes (Fig. 5.4B 
& 5.4C). To compliment the membrane integrity assay, transmission electron microscopy 
(TEM) was also used to image P. aeruginosa after 0 and 30 h of incubation with a PANDA 
disk. At 0 h, an intact membrane is clearly observed (Fig. 5.4D), however after 30 h, TEM 
shows the complete destruction of the cell membrane with crumpled cell envelopes (Fig. 
5.4E). These results show that PANDAs lead to a loss of respiratory activity and damage 
 87 
of cell membrane integrity, indicating that the pA released from PANDAs, can disrupt 
membrane and damage other metabolic functions as previously reported in literature 207-
208. Additionally, other labs have begun to elucidate the specific antimicrobial mechanism 
of pA with evidence demonstrating up/down regulation of genes critical for cellular 
survival 209, and rapid shiff-base formation with amines potentially present in peptides, 
proteins, and DNA/RNA 210. 
 
Figure 5.4 Antibacterial activity of PANDAs. (A) ZOI of PANDA and control disks. 
Plotted data points represent individual measurements. (B) Minimum inhibition assay of 
different sized PANDA disks. (C) Time-dependent killing of pathogens by 100 mm3 
PANDA disks. Data are representative of 2 independent experiments ± s.d. 
 88 
5.4.4 Antifungal activity of PANDAs.  
5.4.4.1 Fungal inhibitory assays 
To further probe the broad spectrum antimicrobial activity of PANDAs, we performed a 
series of assays against the pathogenic fungus H. capsulatum. The invasive nature of H. 
capsulatum coupled with its resistance to most azole-based antifungal treatments makes 
the highly pathogenic H. capsulatum strain G217B, a model fungal system to assess 
PANDA activity.211 As a preliminary experiment, a ZOI assay was performed with a 50 
mm3 PANDA and control disk on yeast-phase H. capsulatum. Complete inhibition of 
growth was observed with the PANDA treatment, whereas no measureable antifungal 
activity was detected for the control disk (Fig. 5.5A). To determine the minimum PANDA 
disk size required to inhibit H. capsulatum, PANDAs of various disk sizes (0-45 mm3) 
were added to freshly passed cells, incubated, and every 24 h, optical density measurements 
were recorded to assess the growth kinetics (Fig. 5.5B). As the size of the PANDA disk 
increased, a reduction in H. capsulatum growth rate was observed, with 45 mm3 disks (32.8 
µg mL-1 released in 24 h) completely inhibiting growth. In contrast, the control disk, as 
expected, displayed a normal growth pattern with initial log phase (1-3 days) followed by 
lag phase (3-7 days), which is consistent with healthy H. capsulatum growth. Interestingly, 
the MIC for the fungus (32.8 µg mL-1) was significantly less than the MIC for the bacteria 
(910 µg mL-1) indicating that the fungus is more sensitive to the PANDA disks than the 
pathogenic bacteria tested. 
5.4.4.2 Fungicidal activity of PANDAs  
To examine the fungicidal activity of the PANDA disks, we utilized an Aqua live/dead cell 
stain and flow cytometry. In brief, an exponential-growing culture of H. capsulatum was 
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split in half where one half of the culture received a control disk and the other half received 
a 50 mm3 PANDA disk.  At 24 h and 48 h after PANDA addition, aliquots were taken and 
subjected to staining, fixation (37% formaldehyde), confocal microscopy, and flow 
cytometry to assess viability. Once complete gating was performed on the sample data, the 
viability was determined as a percent of the survived cells. The Aqua fluorescent dye reacts 
with amines yielding fluorescence, but is unable to penetrate living cells leading to weakly 
fluorescent cells. However, compromised cellular membranes allow the dye to permeate 
the cell, reacting with both cell-wall bound amines and intracellular amines, leading to 
intense fluorescence. As shown in Figure 5.5C, at 48 h post addition the control disk cells 
showed very little, if any fluorescence, indicating that the cell walls are functional and 
intact.  In contrast, treatment with the PANDA disks resulted in intense fluorescence from 
all cells, indicating membrane destabilization and cell death (Fig. 5.5D).  The difference in 
fluorescence intensity is sufficient to quantify living from non-living cells using flow 
cytometry (Fig. 5.5E). As shown in Figure 4.5F, roughly 25% of the H. capsulatum 
population were viable within 24 h for the PANDA treatment, whereas virtually no change 
in viability was observed for the control disk.  After 48 h only 15% of PANDA treated H. 
capsulatum cells remained viable whereas there was again no significant change in 
viability in the control disk.  We can conclude from this assay that the release of pA from 
PANDAs results in potent membrane disruption and that the PANDA disk is not only 
bactericidal but also fungicidal. 
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Figure 5.5 Antifungal activity of PANDAs. (A) ZOI of PANDA and control disks. (B) 
Minimum inhibition assay of different sized PANDA disks. Confocal microscopy images 
of H. capsulatum challenged with control (C) and PANDA disks (D) after 48 h. (E) Flow 
cytometry data of control and PANDA disks after 48 h incubation F) Time-dependent 
killing of pathogens by PANDA. Data are representative of 3 independent experiments ± 
s.d. 
5.4.5 Cytotoxicity analysis 
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Successful antimicrobial agents should possess both potency against pathogens as well as 
low cytotoxicity to host cells. Clinically speaking, pathogens like H. capsulatum are 
difficult to treat because they sequester themselves inside alveolar macrophages, one of the 
most valuable immune cell needed to eradicate them. To evaluate PANDA cytotoxicity, 
two cell lines, including RAW 264.7 murine macrophages and VERO epithelial cells 
(isolated from kidney), were analyzed by directly exposing cells to multiple sizes of 
PANDA disks [0.5 mm3 (18.2 µg mL-1), 1.0 mm3 (36.4 µg mL-1), and 1.5 mm3 (54.6 µg 
mL-1)], 1.5 mm3 control disks, and a native control (blank). Cell viabilities were determined 
using a MTT assay over a 24 h period. MTT is a colorimetric dye that assesses cellular 
metabolic activity. In brief, live viable cells can reduce MTT to an insoluble formazan by 
their native oxidase system, which is accompanied by a change in color to purple that can 
be observed via spectrophotometry.  As shown in Figure 5.6A, both cell lines showed no 
significant decrease in viability (90-100 % viable compared to the native control) after 
exposure to PANDA disks of various sizes (0.5-1.5 mm3), indicating minimal cytotoxicity 
towards host cells. We also qualitatively investigated cell morphologies to ensure no 
changes were observed after PANDA treatments. After 24 h, the cells treated with the 
PANDA disk exhibited indistinguishable morphologies and confluency compared to the 
control disk and native control. Macrophage cells displayed a dominant spherical 
morphology with minimal pseudopodia (Figure 5.6B) whereas epithelial cells displayed a 
spindle like morphology of closely aggregated cells  (Figure 5.6C), both without any signs 
of cytoplasmic vacuolation or granularity around the nucleus. Of significance, the low 
cytotoxicity of PANDAs against macrophages at a concentration that is shown to eradicate 
H. capsulatum holds great promise for clinical applications moving forward. 
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Figure 5.6 Cytocompatability of PANDAs. (A) MTT assay of PANDAs incubated with 
VERO kidney epithelial and RAW 264.7 macrophage cells. (B) Bright-field images of 
macrophage and epithelial cells (C), incubated with either nothing (blank), a 1.5 mm3 
control disk, or a 1.5 mm3 PANDA disk. 
5.5 Conclusion 
In summary, we have demonstrated a potent bio-based PANDA that has the versatility to 
treat both prokaryotic and eukaryotic pathogens through the sustained release of pA over 
time. The sustained release of pA allows many generations of the microbes to be exposed, 
thus successfully clearing even slow growing pathogens such as H. capsulatum. Both 
inhibitory and biocidal activity was measured against bacteria and fungi and found that the 
fungi were significantly more susceptible to the PANDA treatment. Through a combination 
of confocal microscopy and transmission electron microscopy, we showed PANDAs 
primary mode of action is via membrane disruption. Additionally, we demonstrated that 
PANDAs have minimal cytotoxicity towards both epithelial and macrophages which are 
both relevant in immunosuppressed patient response. The PANDA network design coupled 
with the potency of pA has the potential to be a streamline target to add to the arsenal of 
defenses against a broad spectrum of pathogens and bares potential for future in vivo 
experiments. 
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APPENDIX A – Supporting Information for Chapter III 
 
 
Table A.1 General formulation of organic stock solutions for thiol-ene 
photopolymerization in miniemulsion. 
Organic Components Mass [g] Moles [mmol] wt. % 
Diallyl phthalate 2.57 10.44 23.53 
GDMP 2.00 8.39 18.32 
PETMP 0.50 1.02 4.58 
Carvacrol 2.90 19.31 26.56 
p-methoxyphenol 0.05 0.40 0.46 
Irgacure 184 0.10 0.49 0.92 
Hexadecane 0.60 2.65 5.49 
Thymol 2.20 14.65 20.15 
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Figure A.1 1H NMR of starting materials and cured NPs. 
1H NMR of the starting materials: diallyl phthalate, PETMP, GDMP, carvacrol, and all three types of NPs after UV polymerization. 
1H spectrum confirmed the disappearance of both mercaptopriopionate (2.62-2.83 ppm) and alkene (5.07-5.45 ppm and 5.87-6.10 
ppm) peaks after UV exposure. 
 
Figure A.2 Raman spectra of TCNPs after ultrasonication (top, blue) and after exposure to 
UV light (λ365 nm). 
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Figure A.3 A) Surfactant concentration sweep of Hitenol BC-20 and B) Effect of weight 
fraction of the organic monomer phase on particle size for TCNPs. 
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Figure A.4 Transmission electron microscopy of (A) c NPs, (B) CNPs, and (C) TCNPs. 
 
Figure A.5 Absence of antimicrobial activity of B. subtilis by Hitenol BC-20 at 140 and 
70 mM. 
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Figure A.6 Antimicrobial activity of nanoparticles loaded with different ratios of 
carvacrol and thymol (treatments I, II, and III). Controls included empty NPs (IV) and a 
12:4 mixture of pure carvacrol and thymol (V). 
 
Figure A.7 Ramping conditions used for GC-MS separation of thymol and carvacrol 
isomers. 
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Figure A.8 Example separation of thymol and carvacol isomers eluting at 19.40 and 
19.56 min respectively. 
 
Figure A.9 Calibration curves for thymol and carvacrol isomers. 
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Table A.2 Nanoparticle size and concentration for different formulations. 
Sample Particle size (nm) [NP] (particles mL-1) 
Control NPs (Butyl acetate) 183 ± 19 1.4 x 1013 
CNPs (Carvacrol) 148 ± 24 2.7 x 10
13 
TCNPs (Thymol and Carvacrol) 147 ± 19 2.7 x 10
13 
 
 
Figure A.10 Additional data with controls: inhibition of B. subtilis ATCC 6633, E. coli 
ATCC 25922, and S. aureus RN6390 with thiol-ene nanoparticles containing different 
ratios of essential oils (shown in Table S5). 
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Figure A.11 Additional data with controls: Inhibition of E. coli O157:H7 and B. 
cenocepacia K56-2 with different types of NPs. 
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Figure A.12 Absence of antimicrobial activity for different concentrations of carvacrol 
and thymol/carvacrol in 70 mM Hitenol BC-20. 
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Figure A.13 Additional TEM images of E. coli ATCC 25922 with TCNPs over time. 
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Figure A.14 Additional TEM images of B. subtilis ATCC 6633 with TCNPs over time. 
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APPENDIX B – Supporting Information for Chapter IV 
 
Figure B.1 1H NMR of diallyl p-chlorobenzaldehyde acetal.  
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Figure B.2 13C NMR of diallyl p-chlorobenzaldehyde acetal. 
 
 
Figure B.3 Zones of inhibition for small molecule precursors within PANDA 
formulation.  
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Figure B.4 PANDAs exposed to HCl vapor led to complete bulk degradation in minutes 
while ammonium hydroxide vapor led to retarded degradation with no flow observed 
within 24 h. 
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